• Identification of Germline Variants in Patients with Hereditary Cancer Syndromes in Northeast Mexico.
    • Pérez-Ibave DC, Garza-Rodríguez ML, Noriega-Iriondo MF, Flores-Moreno SM, González-Geroniz MI, Espinoza-Velazco A, Castruita-Ávila AL, Alcorta-Núñez F, Zayas-Villanueva OA, González-Guerrero JF, Alcorta-Garza A, Vidal-Gutiérrez O, Burciaga-Flores CH.
    • Genes (Basel). 2023 Jan 28;14(2):341. doi: 10.3390/genes14020341.
    • Evaluation of genetic alterations in Hereditary Cancer Susceptibility genes in the Ashkenazi Jewish Community of Mexico.
    • Díaz Velásquez CE, Gitler R, Antoniano A, Kershenovich Sefchovich R, De La Cruz Montoya A, Martínez Gregorio H, Rojas Jiménez EA, Cortez Cardoso Penha R, Terrazas LI, Wegman-Ostrosky T, Levi-Lahad E, Zabaleta J, Perdomo S, Paniagua FV.
    • Front Genet. 2023 Jan 24;14:1094260. doi: 10.3389/fgene.2023.1094260.
    • Prevalence of Germline BRCA1/2 Variants in Ashkenazi and Non-Ashkenazi Prostate Cancer Populations: A Systematic Review and Meta-Analysis.
    • Cioffi A, De Cobelli O, Veronesi P, La Vecchia C, Maisonneuve P, Corso G.
    • Cancers (Basel). 2023 Jan 2;15(1):306. doi: 10.3390/cancers15010306.
    • Variations in Practice and Geographic Disparities Between Dedicated Multidisciplinary Clinics for BRCA1/BRCA2 Mutation Carriers in Israel.
    • Hermann N, Mor P, Kaidar-Person O, Bernstein-Molho R, Brodsky M, Madorsky Feldman D, Flugelman AA, Aboody Nevo H, Meshoulam Avital D, Sklair-Levy M, Friedman E, Allweis TM.
    • Isr Med Assoc J. 2023 Jan;25(1):18-22.
    • Outcomes of Universal Point-of-Care Genetic Testing in Diverse Patients With Pancreatic Ductal Adenocarcinoma.
    • Drogan CM, Kindler HL, Gao G, Kupfer SS.
    • JCO Precis Oncol. 2023 Jan;7:e2200196. doi: 10.1200/PO.22.00196.
    • Genetic testing women with newly diagnosed breast cancer: What criteria are the most predictive of a positive test?
    • Metcalfe KA, Narod SA, Eisen A, Poll A, Zamani N, McCready D, Cil TD, Wright FC, Lerner-Ellis J, McCuaig J, Graham T, Sun P, Akbari MR.
    • Cancer Med. 2022 Dec 21. doi: 10.1002/cam4.5515. Epub ahead of print.
    • Real World Cost-Effectiveness Analysis of Population Screening for BRCA Variants among Ashkenazi Jews Compared with Family History-Based Strategies.
    • Michaelson-Cohen R, Cohen MJ, Cohen C, Greenberg D, Shmueli A, Lieberman S, Tomer A, Levy-Lahad E, Lahad A.
    • Cancers (Basel). 2022 Dec 12;14(24):6113. doi: 10.3390/cancers14246113.
    • Non-parametric estimation of the age-at-onset distribution from a cross-sectional sample.
    • Mandal S, Qin J, Pfeiffer RM.
    • Biometrics. 2022 Dec 5. doi: 10.1111/biom.13804. Epub ahead of print.
    • Variable number tandem repeats (VNTRs) as modifiers of breast cancer risk in carriers of BRCA1 185delAG.
    • Ding YC, Adamson AW, Bakhtiari M, Patrick C, Park J, Laitman Y, Weitzel JN, Bafna V, Friedman E, Neuhausen SL.
    • Eur J Hum Genet. 2022 Nov 25. doi: 10.1038/s41431-022-01238-z. Epub ahead of print.
    • The Genetics of Pancreatic Cancer
    • [No author given]
    • My Gene Counsel. Genetic Journal. 2022 Nov 14.
    • Racial and ethnic variation in BRCA1 and BRCA2 genetic test results among individuals referred for genetic counseling at a large urban comprehensive cancer center.
    • Abdallah N, Purrington KS, Tatineni S, Assad H, Petrucelli N, Simon MS.
    • Cancer Causes Control. 2022 Nov 12. doi: 10.1007/s10552-022-01648-w. Epub ahead of print.
    • Multigene Panel Testing Yields High Rates of Clinically Actionable Variants Among Patients With Colorectal Cancer.
    • Coughlin SE, Heald B, Clark DF, Nielsen SM, Hatchell KE, Esplin ED, Katona BW.
    • JCO Precis Oncol. 2022 Nov [12];6:e2200517. doi: 10.1200/PO.22.00517.
    • Disparities in cancer genetics care by race/ethnicity among pan-cancer patients with pathogenic germline variants.
    • Liu YL, Maio A, Kemel Y, Salo-Mullen EE, Sheehan M, Tejada PR, Trottier M, Arnold AG, Fleischut MH, Latham A, Carlo MI, Murciano-Goroff YR, Walsh MF, Mandelker D, Mehta N, Bandlamudi C, Arora K, Zehir A, Berger MF, Solit DB, Aghajanian C, Diaz LA Jr, Robson ME, Brown CL, Offit K, Hamilton JG, Stadler ZK.
    • Cancer. 2022 Nov 1;128(21):3870-3879. doi: 10.1002/cncr.34434. Epub 2022 Aug 30.
    • From the patient to the population: Use of genomics for population screening.
    • Mighton C, Shickh S, Aguda V, Krishnapillai S, Adi-Wauran E, Bombard Y.
    • Front Genet. 2022 Oct 24;13:893832. doi: 10.3389/fgene.2022.893832.
    • Contribution of BRCA1 5382insC mutation to triplene-gative and luminal types of breast cancer in Ukraine.
    • Samusieva A, Serga S, Klymenko S, Rybchenko L, Klimuk B, Zakhartseva L, Gorovenko N, Lobanova O, Rossokha Z, Fishchuk L, Levkovich N, Medvedieva N, Popova O, Cheshuk V, Inomistova M, Khranovska N, Skachkova O, Michailovich Y, Ponomarova O, Kozeretska I.
    • Breast Cancer Res Treat. 2022 Oct;195(3):453-459. doi: 10.1007/s10549-022-06692-3. Epub 2022 Aug 5.
    • Hereditary Ovarian Cancer: Towards a Cost-Effective Prevention Strategy.
    • Ghose A, Bolina A, Mahajan I, Raza SA, Clarke M, Pal A, Sanchez E, Rallis KS, Boussios S.
    • Int J Environ Res Public Health. 2022 Sep 23;19(19):12057. doi: 10.3390/ijerph191912057.
    • Getting Past the Shock of a Previvor Diagnosis and Making a Plan.
    • Swirsky N.
    • FORCE. Blog. 2022 Sep 21.
    • Primary care physician referral practices regarding BRCA1/2 genetic counseling in a major health system.
    • Linfield DT, Rothberg MB, Pfoh ER, Noss R, Cassard L, Powers JC, Lipold L, Martinez KA.
    • Breast Cancer Res Treat. 2022 Sep;195(2):153-160. doi: 10.1007/s10549-022-06523-5. Epub 2022 Jul 16.
    • Diagnostic yield and clinical relevance of expanded genetic testing for cancer patients.
    • Ceyhan-Birsoy O, Jayakumaran G, Kemel Y, Misyura M, Aypar U, Jairam S, Yang C, Li Y, Mehta N, Maio A, Arnold A, Salo-Mullen E, Sheehan M, Syed A, Walsh M, Carlo M, Robson M, Offit K, Ladanyi M, Reis-Filho JS, Stadler ZK, Zhang L, Latham A, Zehir A, Mandelker D.
    • Genome Med. 2022 Aug 15;14(1):92. doi: 10.1186/s13073-022-01101-2.
    • Genetic diversity in Kashubs: the regional increase in the frequency of several disease-causing variants.
    • Jankowski M, Daca-Roszak P, Obracht-Prondzynski C, Ploski R, Lipska-Zietkiewicz BS, Zietkiewicz E.
    • J Appl Genet. 2022 Aug 15. doi: 10.1007/s13353-022-00713-z. Epub ahead of print.
    • Evaluating the Effectiveness of a Telehealth Cancer Genetics Program: A BRCA Pilot Study.
    • Rose E, Hardy MW, Gates R, Stanislaw C, Meisel J, Grinzaid KA.
    • Public Health Genomics. 2022 Aug 9:1-14. doi: 10.1159/000525658. Epub ahead of print.
    • Randomised trial of population based BRCA testing in Ashkenazi Jews: Long term secondary lifestyle behavioural outcomes.
    • Burnell M, Gaba F, Sobocan M, Desai R, Sanderson S, Loggenberg K, Gessler S, Side L, Brady AF, Dorkins H, Wallis Y, Jacobs C, Legood R, Beller U, Tomlinson I, Wardle J, Menon U, Jacobs I, Manchanda R.
    • BJOG. 2022 Jul 4. doi: 10.1111/1471-0528.17253. Epub ahead of print.
    • Genetic testing in prostate cancer management: Considerations informing primary care.
    • Giri VN, Morgan TM, Morris DS, Berchuck JE, Hyatt C, Taplin ME.
    • CA Cancer J Clin. 2022 Jul;72(4):360-371. doi: 10.3322/caac.21720. Epub 2022 Feb 24.
    • Re-evaluating cancer risks associated with the CHEK2 p.Ser428Phe Ashkenazi Jewish founder pathogenic variant.
    • Laitman Y, Nielsen SM, Hatchell KE, Truty R, Bernstein-Molho R, Esplin ED, Friedman E.
    • Fam Cancer. 2022 Jul;21(3):305-308. doi: 10.1007/s10689-021-00278-6. Epub 2021 Oct 8.
    • Breast Cancer with Low Recurrence Score on Oncotype DX©: Interplay Between Early Recurrence, Lobular Histology and BRCA Mutation.
    • Zarbiv Y, Wygoda YB, Grinshpun A, Hamburger T, Sella T, Breuer S, Maimon O, Rottenberg Y, Peretz T, Kadouri L.
    • Oncol Ther. 2022 Jun 25. doi: 10.1007/s40487-022-00202-7. Epub ahead of print.
    • Not All Genetic Tests are Created Equal.
    • Cline M, Holdren J.
    • FORCE. Blog. 2022 Jun 14.
    • Population-based BRCA1/2 testing programmes are highly acceptable in the Jewish community: results of the JeneScreen Study.
    • Tiller JM, Cousens NE, Kaur R, Rowley S, Ko YA, Mahale S, Bankier A, Meiser B, Barlow-Stewart K, Burnett L, Jacobs C, James P, Trainer A, Neil S, Campbell IG, Andrews L, Delatycki M.
    • J Med Genet. 2022 Jun 3:jmedgenet-2022-108519. doi: 10.1136/jmedgenet-2022-108519. Epub ahead of print.
    • Brain metastases in patients with ovarian cancer.
    • Limon D, Shachar E, Wolf I, Adar L, Peleg Hasson S, Ferro L, Safra T.
    • Acta Oncol. 2022 Jun;61(6):757-763. doi: 10.1080/0284186X.2022.2066985. Epub 2022 Apr 29.
    • Laboratory-related outcomes from integrating an accessible delivery model for hereditary cancer risk assessment and genetic testing in populations with barriers to access.
    • Amendola LM, Shuster E, Leo MC, Dorschner MO, Rolf BA, Shirts BH, Gilmore MJ, Okuyama S, Zepp JM, Kauffman TL, Mittendorf KF, Bellcross C, Jenkins CL, Joseph G, Riddle L, Syngal S, Ukaegbu C, Goddard KAB, Wilfond BS, Jarvik GP; CHARM Study.
    • Genet Med. 2022 Jun;24(6):1196-1205. doi: 10.1016/j.gim.2022.02.006. Epub 2022 Mar 16.
    • Attitudes and interest in incorporating BRCA1/2 cancer susceptibility testing into reproductive carrier screening for Ashkenazi Jewish men and women.
    • Hardy MW, Peshkin BN, Rose E, Ladd MK, Binion S, Tynan M, McBride CM, Grinzaid KA, Schwartz MD.
    • J Community Genet. 2022 Jun;13(3):281-292. doi: 10.1007/s12687-022-00590-3. Epub 2022 Apr 29.
    • Challenges and Opportunities in Engaging Primary Care Providers in BRCA Testing: Results from the BFOR Study.
    • Pace LE, Tung N, Lee YS, Hamilton JG, Gabriel C, Revette A, Raja S, Jenkins C, Braswell A, Morgan K, Levin J, Block J, Domchek SM, Nathanson K, Symecko H, Spielman K, Karlan B, Kamara D, Lester J, Offit K, Garber JE, Keating NL.
    • J Gen Intern Med. 2022 Jun;37(8):1862-1869. doi: 10.1007/s11606-021-06970-8. Epub 2021 Jun 25.

    Identifier: NCT03351803: BRCA Founder OutReach (BFOR) Study. (ClinicalTrials.gov)

    • Population-based screening of Uruguayan Ashkenazi Jews for recurrent BRCA1 and BRCA2 pathogenic sequence variants.
    • Castillo C, Artagaveytia N, Brignoni L, Laitman Y, Camejo N, Hernández AL, Krygier G, Cayota A, Delgado L, Friedman E.
    • Mol Genet Genomic Med. 2022 Jun;10(6):e1928. doi: 10.1002/mgg3.1928. Epub 2022 Mar 25.
    • Jewish cultural and religious factors and uptake of population-based BRCA testing across denominations: a cohort study.
    • Reisel D, Burnell M, Side L, Loggenberg K, Gessler S, Desai R, Sanderson S, Brady AF, Dorkins H, Wallis Y, Jacobs C, Legood R, Beller U, Tomlinson I, Wardle J, Menon U, Jacobs I, Manchanda R.
    • BJOG. 2022 May;129(6):959-968. doi: 10.1111/1471-0528.16994. Epub 2021 Nov 25.
    • Common founder BRCA2 pathogenic variants and breast cancer characteristics in Ethiopian Jews.
    • Lieberman S, Chen-Shtoyerman R, Levi Z, Shkedi-Rafid S, Zuckerman S, Bernstein-Molho R, Levi GR, Shachar SS, Flugelman A, Libman V, Kedar I, Naftaly-Nathan S, Lagovsky I, Peretz T, Karminsky N, Carmi S, Levy-Lahad E, Goldberg Y.
    • Breast Cancer Res Treat. 2022 May;193(1):217-224. doi: 10.1007/s10549-022-06557-9. Epub 2022 Mar 12.
    • Identification of the most common BRCA alterations through analysis of germline mutation databases: Is droplet digital PCR an additional strategy for the assessment of such alterations in breast and ovarian cancer families?
    • Lavoro A, Scalisi A, Candido S, Zanghì GN, Rizzo R, Gattuso G, Caruso G, Libra M, Falzone L.
    • Int J Oncol. 2022 May;60(5):58. doi: 10.3892/ijo.2022.5349. Epub 2022 Apr 6.
    • Not All Genetic Tests are Created Equal.
    • Cline M, Holdren J.
    • BRCA Exchange. 2022 Apr 14.
    • Partner Spotlight: Sharsheret.
    • Montoto R.
    • FORCE. Blog. 2022 Apr 8.
    • Genetic Testing for All: Overcoming Disparities in Ovarian Cancer Genetic Testing.
    • Frey MK, Finch A, Kulkarni A, Akbari MR, Chapman-Davis E.
    • Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-12. doi: 10.1200/EDBK_350292.
    • BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis.
    • Nyberg T, Tischkowitz M, Antoniou AC.
    • Br J Cancer. 2022 Apr;126(7):1067-1081. doi: 10.1038/s41416-021-01675-5. Epub 2021 Dec 28.
    • Recurring pathogenic variants in the BRCA2 gene in the Ethiopian Jewish population. Founder mutations?
    • Ludman MD, Philipsborn SL, Hartmajer S, Shwartzman NS, Reinstein E.
    • Fam Cancer. 2022 Apr;21(2):121-123. doi: 10.1007/s10689-021-00255-z. Epub 2022 Feb 15.
    • CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer.
    • Adib E, El Zarif T, Nassar AH, Akl EW, Abou Alaiwi S, Mouhieddine TH, Esplin ED, Hatchell K, Nielsen SM, Rana HQ, Choueiri TK, Kwiatkowski DJ, Sonpavde G.
    • Br J Cancer. 2022 Mar;126(5):797-803. doi: 10.1038/s41416-021-01673-7. Epub 2021 Dec 23.
    • Racial and ethnic variation in multigene panel testing in a cohort of BRCA1/2-negative individuals who had genetic testing in a large urban comprehensive cancer center.
    • Tatineni S, Tarockoff M, Abdallah N, Purrington KS, Assad H, Reagle R, Petrucelli N, Simon MS.
    • Cancer Med. 2022 Mar;11(6):1465-1473. doi: 10.1002/cam4.4541. Epub 2022 Jan 17.
    • The risks of breast and ovarian cancer associated with the Ashkenazi Jewish founder allele BRCA2 6174delT.
    • Finch A, Metcalfe K, Akbari M, Friedman E, Tung N, Rosen B, Eisen A, Karlan B, Foulkes W, Neuhausen SL, Senter L, McKinnon W, Elser C, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.
    • Clin Genet. 2022 Mar;101(3):317-323. doi: 10.1111/cge.14098. Epub 2022 Jan 26.
    • Targeted BRCA1/2 population screening among Ashkenazi Jewish individuals using a web-enabled medical model: An observational cohort study.
    • Morgan KM, Hamilton JG, Symecko H, Kamara D, Jenkins C, Lester J, Spielman K, Pace LE, Gabriel C, Levin JD, Tejada PR, Braswell A, Marcell V, Wildman T, Devolder B, Baum RC, Block JN, Fesko Y, Boehler K, Howell V, Heitler J, Robson ME, Nathanson KL, Tung N, Karlan BY, Domchek SM, Garber JE, Offit K.
    • Genet Med. 2022 Mar;24(3):564-575. doi: 10.1016/j.gim.2021.10.016. Epub 2021 Dec 3.
    • Genetic predisposition to prostate cancer: an update.
    • Ni Raghallaigh H, Eeles R.
    • Fam Cancer. 2022 Jan;21(1):101-114. doi: 10.1007/s10689-021-00227-3. Epub 2021 Jan 24.
    • Can Social Media Be Used as a Community-Building and Support Tool among Jewish Women Impacted by Breast and Ovarian Cancer? An Evidence-Based Observational Report.
    • Dunn C, Campbell S, Marku N, Fleischmann A, Silber E, Rosen M, Tercyak KP.
    • Healthcare (Basel). 2021 Dec 28;10(1):51. doi: 10.3390/healthcare10010051.
    • Conference Session Highlight: I'm Not White, Can I Still Have a Mutation?
    • Stallings E, Goldberg D.
    • FORCE. Blog. 2021 Nov 19.
    • Pathogenic BRCA Variants as Biomarkers for Risk in Prostate Cancer.
    • McNevin CS, Cadoo K, Baird AM, Murchan P, Sheils O, McDermott R, Finn S.
    • Cancers (Basel). 2021 Nov 14;13(22):5697. doi: 10.3390/cancers13225697.
    • Yield of targeted genotyping for the recurring pathogenic variants in cancer susceptibility genes in a healthy, multiethnic Israeli population.
    • Bernstein-Molho R, Galmor L, Laitman Y, Segev S, Friedman E.
    • Cancer. 2021 Oct 1;127(19):3599-3604. doi: 10.1002/cncr.33560. Epub 2021 Jun 22.
    • Racial and Ethnic Differences in Multigene Hereditary Cancer Panel Test Results for Women With Breast Cancer.
    • Yadav S, LaDuca H, Polley EC, Hu C, Niguidula N, Shimelis H, Lilyquist J, Na J, Lee KY, Gutierrez S, Yussuf A, Hart SN, Davis BT, Chao EC, Pesaran T, Goldgar DE, Dolinsky JS, Couch FJ.
    • J Natl Cancer Inst. 2021 Oct 1;113(10):1429-1433. doi: 10.1093/jnci/djaa167.
    • Building the What Comes Next Cohort for BRCA1 and BRCA2 testing: a descriptive analysis.
    • Dossa F, Metcalfe K, Sutradhar R, Little T, Eisen A, Chun K, Meschino WS, Velsher L, Ellis JL, Baxter NN.
    • CMAJ Open. 2021 Sep 21;9(3):E874-E885. doi: 10.9778/cmajo.20200228.
    • The importance of Ethnicity: are breast cancer Polygenic Risk Scores ready for women who are not of white European origin?
    • Evans DG, van Veen EM, Byers H, Roberts E, Howell A, Howell SJ, Harkness EF, Brentnall A, Cuzick J, Newman WG.
    • Int J Cancer. 2021 Aug 30. doi: 10.1002/ijc.33782. Epub ahead of print.
    • Preventive population genomics: The model of BRCA related cancers.
    • Reisel D, Baran C, Manchanda R.
    • Adv Genet. 2021;108:1-33. doi: 10.1016/bs.adgen.2021.08.001. Epub 2021 Aug 26.
    • Review. Book chapter
    • A rare case of breast cancer in a transgender woman.
    • Sieberg R, Soriano K, Zuurbier R.
    • Radiol Case Rep. 2021 Aug 26;16(11):3285-3288. doi: 10.1016/j.radcr.2021.07.052.
    • Overview of Prostate Cancer Genetic Testing.
    • Chandrasekar T, Kelly WK, Gomella LG.
    • Urol Clin North Am. 2021 Aug;48(3):279-282. doi: 10.1016/j.ucl.2021.04.002. Epub 2021 Jun 10.
    • Review
    • BRCA, breast cancer and in vitro fertilization: How should we advise our patients?
    • García-Planells J, Francés BS, Diez-Juan A.
    • Fertil Steril. 2021 Jul 8:S0015-0282(21)00505-7. doi: 10.1016/j.fertnstert.2021.06.011. Epub ahead of print.

    Original research:

    Fertility treatments and breast cancer risk in Jewish Israeli BRCA mutation carriers.

    • Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis.
    • Casolino R, Paiella S, Azzolina D, Beer PA, Corbo V, Lorenzoni G, Gregori D, Golan T, Braconi C, Froeling FEM, Milella M, Scarpa A, Pea A, Malleo G, Salvia R, Bassi C, Chang DK, Biankin AV.
    • J Clin Oncol. 2021 Jul 1:JCO2003238. doi: 10.1200/JCO.20.03238. Epub ahead of print.
    • Age at diagnosis of cancer in 185delAG BRCA1 mutation carriers of diverse ethnicities: tentative evidence for modifier factors.
    • Laitman Y, Michaelson-Cohen R, Chen-Shtoyerman R, Goldberg Y, Reish O, Bernstein-Molho R, Levy-Lahad E, Baruch NEB, Kedar I, Evans DG, Haim S, Paluch-Shimon S, Friedman E.
    • Fam Cancer. 2021 Jul;20(3):189-194. doi: 10.1007/s10689-020-00216-y. Epub 2020 Nov 9.
    • Evaluation of two population screening programmes for BRCA1/2 founder mutations in the Australian Jewish community: a protocol paper.
    • Cousens NE, Tiller J, Meiser B, Barlow-Stewart K, Rowley S, Ko YA, Mahale S, Campbell IG, Kaur R, Bankier A, Burnett L, Jacobs C, James PA, Trainer A, Neil S, Delatycki MB, Andrews L.
    • BMJ Open. 2021 Jun 25;11(6):e041186. doi: 10.1136/bmjopen-2020-041186.
    • Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study.
    • Safra T, Waissengrin B, Gerber D, Bernstein-Molho R, Klorin G, Salman L, Josephy D, Chen-Shtoyerman R, Bruchim I, Frey MK, Pothuri B, Muggia F.
    • Gynecol Oncol. 2021 Jun 22:S0090-8258(21)00489-3. doi: 10.1016/j.ygyno.2021.06.009. Epub ahead of print.
    • Ashkenazi Dads Can Pass the BRCA Mutation to Their Kids. It Turns Out I Did.
    • Hertz B.
    • Kveller. 2021 Jun 14.

    Blog post: Surviving, and Thriving, as a Dad with a Cancer Gene Mutation. (FORCE Blog)

    • Double heterozygotes of BRCA1/BRCA2 and mismatch repair gene pathogenic variants: case series and clinical implications.
    • Laish I, Friedman E, Levi-Reznick G, Kedar I, Katz L, Levi Z, Halpern N, Parnasa S, Abu-Shatya A, Half E, Goldberg Y.
    • Breast Cancer Res Treat. 2021 Jun 4. doi: 10.1007/s10549-021-06258-9. Epub ahead of print.
    • Health Care Disparities and Demand for Expanding Hereditary Breast Cancer Screening Guidelines in African Americans.
    • Ciuro J, Beyer A, Fritzler J, Jackson N, Ahsan S.
    • Clin Breast Cancer. 2021 Jun;21(3):e220-e227. doi: 10.1016/j.clbc.2020.08.010. Epub 2020 Sep 3.
    • Re: ERCC3, a new ovarian cancer susceptibility gene?
    • Soukupova J, Zemankova P, Nehasil P, Kleibl Z; CZECANCA consortium.
    • Eur J Cancer. 2021 Jun;150:278-280. doi: 10.1016/j.ejca.2021.03.014. Epub 2021 Apr 21.
    • Letter, Comment

    Original research:

    ERCC3, a new ovarian cancer susceptibility gene?

    Letter, Reply:

    Response to letter entitled: Re: ERCC3 a new ovarian cancer susceptibility gene?

    • Genetic counselor approaches to BRCA1/2 direct-to-consumer genetic testing results.
    • Burke S, Mork M, Qualmann K, Woodson A, Jin Ha M, Arun B, Kaulfus M.
    • J Genet Couns. 2021 Jun;30(3):803-812. doi: 10.1002/jgc4.1380. Epub 2021 Feb 6.
    • Study of the Genetic Variants in BRCA1/2 and Non-BRCA Genes in a Population-Based Cohort of 2155 Breast/Ovary Cancer Patients, Including 443 Triple-Negative Breast Cancer Patients, in Argentina.
    • Solano AR, Mele PG, Jalil FS, Liria NC, Podesta EJ, Gutiérrez LG.
    • Cancers (Basel). 2021 May 31;13(11):2711. doi: 10.3390/cancers13112711.
    • BRCA mutated pancreatic cancer: A change is coming.
    • Rosen MN, Goodwin RA, Vickers MM.
    • World J Gastroenterol. 2021 May 7;27(17):1943-1958. doi: 10.3748/wjg.v27.i17.1943.
    • Germline Genetics of Prostate Cancer: Prevalence of Risk Variants and Clinical Implications for Disease Management.
    • Doan DK, Schmidt KT, Chau CH, Figg WD.
    • Cancers (Basel). 2021 Apr 29;13(9):2154. doi: 10.3390/cancers13092154.
    • Volunteer Spotlight – Tanya Temkin.
    • Temkin T.
    • FORCE. Blog. 2021 Apr 29.
    • A New Insight for the Identification of Oncogenic Variants in Breast and Prostate Cancers in Diverse Human Populations, With a Focus on Latinos.
    • Varela NM, Guevara-Ramírez P, Acevedo C, Zambrano T, Armendáriz-Castillo I, Guerrero S, Quiñones LA, López-Cortés A.
    • Front Pharmacol. 2021 Apr 12;12:630658. doi: 10.3389/fphar.2021.630658.
    • Fertility treatments and breast cancer risk in Jewish Israeli BRCA mutation carriers.
    • Perri T, Naor-Revel S, Eliassi-Revivo P, Lifshitz D, Friedman E, Korach J.
    • Fertil Steril. 2021 Apr 3:S0015-0282(21)00148-5. doi: 10.1016/j.fertnstert.2021.02.030. Epub ahead of print.

    Commentary:

    BRCA, breast cancer and in vitro fertilization: How should we advise our patients?

    • Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
    • Pujol P, Barberis M, Beer P, Friedman E, Piulats JM, Capoluongo ED, Garcia Foncillas J, Ray-Coquard I, Penault-Llorca F, Foulkes WD, Turnbull C, Hanson H, Narod S, Arun BK, Aapro MS, Mandel JL, Normanno N, Lambrechts D, Vergote I, Anahory M, Baertschi B, Baudry K, Bignon YJ, Bollet M, Corsini C, Cussenot O, De la Motte Rouge T, Duboys de Labarre M, Duchamp F, Duriez C, Fizazi K, Galibert V, Gladieff L, Gligorov J, Hammel P, Imbert-Bouteille M, Jacot W, Kogut-Kubiak T, Lamy PJ, Nambot S, Neuzillet Y, Olschwang S, Rebillard X, Rey JM, Rideau C, Spano JP, Thomas F, Treilleux I, Vandromme M, Vendrell J, Vintraud M, Zarca D, Hughes KS, Alés Martínez JE.
    • Eur J Cancer. 2021 Feb 9;146:30-47. doi: 10.1016/j.ejca.2020.12.023. Epub ahead of print.
    • Implementing genomic screening in diverse populations.
    • Abul-Husn NS, Soper ER, Braganza GT, Rodriguez JE, Zeid N, Cullina S, Bobo D, Moscati A, Merkelson A, Loos RJF, Cho JH, Belbin GM, Suckiel SA, Kenny EE.
    • Genome Med. 2021 Feb 5;13(1):17. doi: 10.1186/s13073-021-00832-y.
    • Double heterozygosity for TP53 and BRCA1 mutations: clinical implications in populations with founder mutations.
    • Shani H, Bernstein-Molho R, Laitman Y, Netzer I, Friedman E.
    • Breast Cancer Res Treat. 2021 Jan 15. doi: 10.1007/s10549-020-06084-5. Epub ahead of print.
    • Case report
    • Cost effectiveness of whole population BRCA genetic screening for cancer prevention in Israel.
    • Michaan N, Leshno M, Safra T, Sonnenblick A, Laskov I, Grisaru D.
    • Cancer Prev Res (Phila). 2020 Dec 22:canprevres.0411.2020. doi: 10.1158/1940-6207.CAPR-20-0411. Epub ahead of print.
    • ERCC3, a new ovarian cancer susceptibility gene?
    • Stradella A, Del Valle J, Rofes P, Vargas-Parra G, Salinas M, González S, Montes E, López-Doriga A, Gómez C, de Cid R, Darder E, Teulé A, Solanes A, Munté E, Capellà G, Pineda M, Feliubadaló L, Brunet J, Lázaro C.
    • Eur J Cancer. 2020 Dec;141:1-8. doi: 10.1016/j.ejca.2020.09.023. Epub 2020 Oct 23.

    Letter, Comment:

    Re: ERCC3, a new ovarian cancer susceptibility gene?

    Letter, Reply:

    Response to letter entitled: Re: ERCC3 a new ovarian cancer susceptibility gene?

    • Clinical Characteristics and Prognosis of Gastric Cancer Patients with BRCA 1/2 Germline Mutations: Report of Ten Cases and a Literature Review.
    • Halpern N, Grinshpun A, Boursi B, Golan T, Margalit O, Aderka D, Friedman E, Laitman Y, Hubert A, Kadouri L, Hamburger T, Barnes-Kedar I, Levi Z, Ben-Aharon I, Brenner B, Goldberg Y, Peretz T, Shacham-Shmueli E.
    • Onco Targets Ther. 2020 Nov 13;13:11637-11644. doi: 10.2147/OTT.S276814.
    • An ATM Gene Mutation Caused My Breast Cancer
    • Cohen E.
    • FORCE. Blog. 2020 Nov 12.
    • Germline BRCA1 mutated esophageal squamous cell carcinoma.
    • Starr J, Ramnaraign B.
    • Rare Tumors. 2020 Nov 5;12:2036361320972218. doi: 10.1177/2036361320972218.
    • Knowing about an inherited BRCA mutation improves outcomes for women with breast cancer.
    • [No author given]
    • FORCE. XRAY. 2020 Oct 26.

    Original research:

    Presymptomatic Awareness of Germline Pathogenic BRCA Variants and Associated Outcomes in Women With Breast Cancer.

    • Prevalence of Germline Pathogenic and Likely Pathogenic Variants in Patients With Second Breast Cancers.
    • Yao K KA, Clifford J, Li S, LaDuca H, Hulick P, Gutierrez S, Black MH.
    • JNCI Cancer Spectr. 2020 Oct 26;4(6):pkaa094. doi: 10.1093/jncics/pkaa094.
    • BRCA1 and BRCA2 genes mutations among high risk breast cancer patients in Jordan.
    • Abu-Helalah M, Azab B, Mubaidin R, Ali D, Jafar H, Alshraideh H, Drou N, Awidi A.
    • Sci Rep. 2020 Oct 16;10(1):17573. doi: 10.1038/s41598-020-74250-2.
    • Adherence to NCCN Guidelines for Genetic Testing in Breast Cancer Patients: Who Are We Missing?
    • Alberty-Oller JJ, Weltz S, Santos A, Pisapati K, Ru M, Weltz C, Schmidt H, Port E.
    • Ann Surg Oncol. 2020 Sep 11. doi: 10.1245/s10434-020-09123-z. Epub ahead of print.
    • Presymptomatic Awareness of Germline Pathogenic BRCA Variants and Associated Outcomes in Women With Breast Cancer.
    • Hadar T, Mor P, Amit G, Lieberman S, Gekhtman D, Rabinovitch R, Levy-Lahad E.
    • JAMA Oncol. 2020 Sep 1;6(9):1460-1463. doi: 10.1001/jamaoncol.2020.2059.

    Research news: Study Sees Survival Boost For BRCA1/2 Carriers Tested Before Breast Cancer Diagnosis. (GenomeWeb)

    Research news: 'Knowledge Is Power': Knowing BRCA1/2 Status Tied to Survival. (Medscape)

    Research news: Knowing about an inherited BRCA mutation improves outcomes for women with breast cancer. (FORCE. XRAY.)

    • Imaging-based prostate cancer screening among BRCA mutation carriers-results from the first round of screening.
    • Segal N, Ber Y, Benjaminov O, Tamir S, Yakimov M, Kedar I, Rosenbaum E, Sela S, Ozalvo R, Shavit-Grievink L, Keder D, Baniel J, Margel D.
    • Ann Oncol. 2020 Aug 27:S0923-7534(20)39937-3. doi: 10.1016/j.annonc.2020.06.025. Epub ahead of print.
    • Can population BRCA screening be applied in non-Ashkenazi Jewish populations? Experience in Macau population.
    • Qin Z, Kuok CN, Dong H, Jiang L, Zhang L, Guo M, Leong HK, Wang L, Meng G, Wang SM.
    • J Med Genet. 2020 Aug 17:jmedgenet-2020-107181. doi: 10.1136/jmedgenet-2020-107181. Epub ahead of print.
    • Ancestry-specific hereditary cancer panel yields: Moving toward more personalized risk assessment.
    • Roberts ME, Susswein LR, Janice Cheng W, Carter NJ, Carter AC, Klein RT, Hruska KS, Marshall ML.
    • J Genet Couns. 2020 Aug;29(4):598-606. doi: 10.1002/jgc4.1257. Epub 2020 Mar 30.
    • Germlines 'Rich Source' of Prostate Cancer Info.
    • O'Rourke K, Giri V.
    • Medscape Oncology. 2020 Jul 21.
    • Adherence to National Comprehensive Cancer Network Guidelines for BRCA testing among high risk breast Cancer patients: a retrospective chart review study.
    • Bobbili P, Olufade T, DerSarkissian M, Shenolikar R, Yu H, Duh MS, Tung N.
    • Hered Cancer Clin Pract. 2020 Jun 6;18:13. doi: 10.1186/s13053-020-00144-z.
    • BFOR Study Uses Digital Tools to Facilitate Population BRCA Screening in Ashkenazi Jewish Community.
    • Anderson A.
    • Precision Oncology News. 2020 Jun 3.
    • Mutation prevalence tables for hereditary cancer derived from multi-gene panel testing.
    • Hart SN, Polley EC, Yussuf A, Yadav S, Goldgar DE, Hu C, LaDuca H, Smith LP, Fujimoto J, Li S, Couch FJ, Dolinsky JS.
    • Hum Mutat. 2020 May 22. doi: 10.1002/humu.24053. Epub ahead of print.
    • Haplotypic characterization of BRCA1 c.5266dupC, the prevailing mutation in Brazilian hereditary breast/ovarian cancer.
    • Gomes R, Soares BL, Felicio PS, Michelli R, Netto CBO, Alemar B, Ashton-Prolla P, Palmero EI, Moreira MÂM.
    • Genet Mol Biol. 2020 May 20;43(2):e20190072. doi: 10.1590//1678-4685-GMB-2019-0072.
    • Population-based Genetic Testing for Precision Prevention.
    • Evans O, Manchanda R.
    • Cancer Prev Res (Phila). 2020 May 14:canprevres.0002.2020. doi: 10.1158/1940-6207.CAPR-20-0002. Epub ahead of print.
    • Commentary
    • Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry.
    • Tennen RI, Laskey SB, Koelsch BL, McIntyre MH, Tung JY.
    • Sci Rep. 2020 May 6;10(1):7669. doi: 10.1038/s41598-020-63466-x.
    • Invitae Study Finds Germline Risk Variants in Wide Range of Prostate Cancer Patients.
    • Anderson A.
    • GenomeWeb. Technology. Sequencing. 2020 May 5.
    • Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
    • Demir S, Tozkir H, Gurkan H, Atli EI, Yalcintepe S, Atli E, Sezer YA, Eker D, Tuncbilek N, Tastekin E, Ozen Y, Cicin I.
    • J BUON. 2020 May-Jun;25(3):1337-1347.
    • Population Screening for Inherited Predisposition to Breast and Ovarian Cancer.
    • Manchanda R, Lieberman S, Gaba F, Lahad A, Levy-Lahad E.
    • Annu Rev Genomics Hum Genet. 2020 Apr 21. doi: 10.1146/annurev-genom-083118-015253. [Epub ahead of print]
    • Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer.
    • Golan T, Barenboim A, Lahat G, Nachmany I, Goykhman Y, Shacham-Shmueli E, Halpern N, Brazowski E, Geva R, Wolf I, Goldes Y, Ben-Haim M, Klausner JM, Lubezky N.
    • Ann Surg Oncol. 2020 Apr 20. doi: 10.1245/s10434-020-08469-8. [Epub ahead of print]

    Research review, Commentary:

    ASO Author Reflections: Pancreatic Cancer Patients with Germline BRCA Mutations Benefit from Early Introduction of Platinum-Based Chemotherapy.

    • Diagnostic yield of multigene panel testing in an Israeli cohort: enrichment of low-penetrance variants.
    • Bernstein-Molho R, Friedman E, Kedar I, Laitman Y, Allweis TM, Gal-Yam EN, Feldman HB, Grinshpun A, Halpern N, Hartmajer S, Kadouri L, Katz LH, Kaufman B, Laish I, Levanon K, Philipsborn SL, Ludman M, Moran G, Peretz T, Reinstein E, Levi GR, Safra T, Shkedi S, Vinkler C, Levy Z, Goldberg Y.
    • Breast Cancer Res Treat. 2020 Apr 18. doi: 10.1007/s10549-020-05633-2. [Epub ahead of print]
    • Risk of colorectal cancer associated with BRCA1 and/or BRCA2 mutation carriers: systematic review and meta-analysis.
    • Cullinane CM, Creavin B, O'Connell EP, Kelly L, O'Sullivan MJ, Corrigan MA, Redmond HP.
    • Br J Surg. 2020 Apr 16. doi: 10.1002/bjs.11603. [Epub ahead of print]
    • Review
    • Facilitated referral pathway for genetic testing at the time of ovarian cancer diagnosis: uptake of genetic counseling and testing and impact on patient-reported stress, anxiety and depression.
    • Frey MK, Lee SS, Gerber D, Schwartz ZP, Martineau J, Lutz K, Reese E, Dalton E, Olsen A, Girdler J, Pothuri B, Boyd L, Curtin JP, Levine DA, Blank SV.
    • Gynecol Oncol. 2020 Apr;157(1):280-286. doi: 10.1016/j.ygyno.2020.01.007. Epub 2020 Feb 11.
    • NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.
    • Daly MB, Pilarski R, Yurgelun MB, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Garber JE, Goggins M, Hutton ML, Khan S, Klein C, Kohlmann W, Kurian AW, Laronga C, Litton JK, Mak JS, Menendez CS, Merajver SD, Norquist BS, Offit K, Pal T, Pederson HJ, Reiser G, Shannon KM, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Dwyer MA, Darlow SD.
    • J Natl Compr Canc Netw. 2020 Apr;18(4):380-391. doi: 10.6004/jnccn.2020.0017.

    Continuing Education course: NCCN Guidelines® Insights - Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. (NCCN Continuing Education)

    • Ethnic disparities in the frequency of cancer reported in family histories.
    • Maves H, Flodman P, Nathan D, Smith M.
    • J Genet Couns. 2020 Mar 28. doi: 10.1002/jgc4.1264. [Epub ahead of print]
    • Updated Guideline Moves Genetic Testing Beyond BRCA.
    • Narozniak R.
    • OncologyLive. 2020 Mar 13;21(6).
    • News

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    • Population-based genetic testing for Women's cancer prevention.
    • Evans O, Gaba F, Manchanda R.
    • Best Pract Res Clin Obstet Gynaecol. 2020 Mar 2. pii: S1521-6934(20)30034-1. doi: 10.1016/j.bpobgyn.2020.02.007. [Epub ahead of print]
    • Breast Cancer in Men: A Single Center Experience Over a Period of 22 years.
    • Hoffman A, Ben Ishay O, Horesh N, Shabtai M, Forschmidt E, Rosin D, Gutman M, Ram E.
    • Isr Med Assoc J. 2020 Mar;22(3):160-163.
    • Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial.
    • Golan T, Kindler HL, Park JO, Reni M, Macarulla T, Hammel P, Van Cutsem E, Arnold D, Hochhauser D, McGuinness D, Locker GY, Goranova T, Schatz P, Liu YZ, Hall MJ.
    • J Clin Oncol. 2020 Feb 19:JCO1901890. doi: 10.1200/JCO.19.01890. [Epub ahead of print]
    • Radiation Associated Secondary Malignancies in BRCA Mutation Carriers Treated for Breast Cancer.
    • Schlosser S, Rabinovitch R, Shatz Z, Galper S, Shahadi-Dromi I, Finkel S, Jacobson G, Rasco A, Friedman E, Laitman Y, Evron E, Bernstein R, Weiss I, Levy MS, Ben-David MA.
    • Int J Radiat Oncol Biol Phys. 2020 Feb 18. pii: S0360-3016(20)30219-4. doi: 10.1016/j.ijrobp.2020.02.020. [Epub ahead of print]
    • Experts say more women should be tested for BRCA1 and BRCA2 genetic mutations.
    • Printz C.
    • Cancer. 2020 Feb 15;126(4):693. doi: 10.1002/cncr.32723.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    • Exome sequencing reveals a high prevalence of BRCA1 and BRCA2 founder variants in a diverse population-based biobank.
    • Abul-Husn NS, Soper ER, Odgis JA, Cullina S, Bobo D, Moscati A, Rodriguez JE; CBIPM Genomics Team; Regeneron Genetics Center, Loos RJF, Cho JH, Belbin GM, Suckiel SA, Kenny EE.
    • Genome Med. 2019 Dec 31;12(1):2. doi: 10.1186/s13073-019-0691-1.
    • Online BRCA1/2 screening in the Australian Jewish community: a qualitative study.
    • Yuen J, Cousens N, Barlow-Stewart K, O'Shea R, Andrews L.
    • J Community Genet. 2019 Dec 26. doi: 10.1007/s12687-019-00450-7. [Epub ahead of print]
    • NCCN Publishes Updated Genetic Risk Assessment Recommendations.
    • Wright K.
    • Cancernetwork. 2019 Dec 18.
    • BRCA and Motherhood: A Matter of Time and Timing.
    • Possick C, Kestler-Peleg M.
    • Qual Health Res. 2019 Dec 7:1049732319885113. doi: 10.1177/1049732319885113. [Epub ahead of print]
    • Update: Genetic causes of hereditary pancreatic cancer: BRCA and beyond
    • [No author given]
    • FORCE. XRAYS. 2019 Nov 26.
    • Ethnic disparities among men with prostate cancer undergoing germline testing.
    • Kwon DH, Borno HT, Cheng HH, Zhou AY, Small EJ.
    • Urol Oncol. 2019 Oct 17. pii: S1078-1439(19)30361-8. doi: 10.1016/j.urolonc.2019.09.010. [Epub ahead of print]
    • Prostate cancer genetic testing: NCCN familial high-risk assessment: breast/ovarian.
    • Daly MB.
    • Can J Urol. 2019 Oct;26(5S2):29-30.
    • Breast Cancer Screening in High-Risk Men: A 12-Year Longitudinal Observational Study of Male Breast Imaging Utilization and Outcomes.
    • Gao Y, Goldberg JE, Young TK, Babb JS, Moy L, Heller SL.
    • Radiology. 2019 Sep 17:190971. doi: 10.1148/radiol.2019190971. [Epub ahead of print]

    Press: Men at High Risk for Breast Cancer May Benefit From Screening. (Medscape Oncology)

    • Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization.
    • Kadouri L, Rottenberg Y, Zick A, Hamburger T, Lipson D, Peretz T, Nechushtan H.
    • Lung Cancer. 2019 Sep 12;137:48-51. doi: 10.1016/j.lungcan.2019.09.008. [Epub ahead of print]
    • Randomised trial of population-based BRCA testing in Ashkenazi Jews: long-term outcomes.
    • Manchanda R, Burnell M, Gaba F, Desai R, Wardle J, Gessler S, Side L, Sanderson S, Loggenberg K, Brady AF, Dorkins H, Wallis Y, Chapman C, Jacobs C, Legood R, Beller U, Tomlinson I, Menon U, Jacobs I.
    • BJOG. 2019 Sep 10. doi: 10.1111/1471-0528.15905. [Epub ahead of print]
    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
    • US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW Jr, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB.
    • JAMA. 2019 Aug 20;322(7):652-665. doi: 10.1001/jama.2019.10987.

    Evidence report, Review:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

    Guidelines [Internet]:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force [Internet].

    Editorial:

    Broadening Criteria for BRCA1/2 Evaluation: Placing the USPSTF Recommendation in Context.

    Editorial:

    USPSTF Recommendations for BRCA1 and BRCA2 Testing in the Context of a Transformative National Cancer Control Plan.

    Editorial:

    Hereditary Cancer Evaluation in 2019-a Rapidly Evolving Landscape.

    Editorial:

    US Preventive Services Task Force Breast Cancer Recommendation Statement on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer.

    News:

    USPSTF Calls for More BRCA Screening.

    Patient Page:

    Should I Be Tested for BRCA Mutations?

    Audio Interview, CME Activity: USPSTF Recommendation: Assessment, Counseling, and Testing for BRCA-Related Cancer. (JAMA)

    Press: USPSTF Recommendations on BRCA Mutation Testing. (Medscape Oncology)

    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    • Nelson HD, Pappas M, Cantor A, Haney E, Holmes R.
    • JAMA. 2019 Aug 20;322(7):666-685. doi: 10.1001/jama.2019.8430.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force [Internet].

    • Should I Be Tested for BRCA Mutations?
    • Jin J.
    • JAMA. 2019 Aug 20;322(7):702. doi: 10.1001/jama.2019.11251.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    • USPSTF Recommendation: Assessment, Counseling, and Testing for BRCA-Related Cancer.
    • Mangione CM.
    • JAMA. 2019 Aug 20.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force [Internet].
    • Nelson HD, Pappas M, Cantor A, Haney E, Holmes R, Stillman L.
    • Rockville (MD): Agency for Healthcare Research and Quality (US); 2019 Aug. Report No.: 19-05251-EF-1. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

    • Multi-Gene Panel Testing of 23,179 Individuals for Hereditary Cancer Risk Identifies Pathogenic Variant Carriers Missed by Current Genetic Testing Guidelines.
    • Neben CL, Zimmer AD, Stedden W, van den Akker J, O'Connor R, Chan RC, Chen E, Tan Z, Leon A, Ji J, Topper S, Zhou AY.
    • J Mol Diagn. 2019 Jun 10. pii: S1525-1578(18)30334-9. doi: 10.1016/j.jmoldx.2019.03.001. [Epub ahead of print]

    Press: Multi-Gene Panel Testing Finds Pathogenic Variant Carriers Missed Under Current Testing Guidelines. (GenomeWeb)

    • Understanding Factors Associated with Uptake of BRCA1/2 Genetic Testing among Orthodox Jewish Women in the USA Using a Mixed-Methods Approach.
    • Trivedi MS, Colbeth H, Yi H, Vanegas A, Starck R, Chung WK, Appelbaum PS, Kukafka R, Schechter I, Crew KD.
    • Public Health Genomics. 2019 Jun 4:1-11. doi: 10.1159/000499852. [Epub ahead of print]
    • Cases and evidence for panel testing in cancer genetics: Is site-specific testing dead?
    • Thomas MH, Higgs LK, Modesitt SC, Schroen AT, Ring KL, Dillon PM.
    • J Genet Couns. 2019 Jun;28(3):700-707. doi: 10.1002/jgc4.1044. Epub 2019 Feb 1.
    • Case report
    • Attitude towards and factors affecting uptake of population-based BRCA testing in the Ashkenazi Jewish population: a cohort study.
    • Manchanda R, Burnell M, Gaba F, Sanderson S, Loggenberg K, Gessler S, Wardle J, Side L, Desai R, Brady AF, Dorkins H, Wallis Y, Chapman C, Jacobs C, Tomlinson I, Beller U, Menon U, Jacobs I.
    • BJOG. 2019 May;126(6):784-794. doi: 10.1111/1471-0528.15654. Epub 2019 Mar 18.
    • Fifteen-year survival of invasive epithelial ovarian cancer in women with BRCA1/2 mutations - the National Israeli Study of Ovarian Cancer.
    • Lavie O, Chetrit A, Novikov I, Sadetzki S; National Israeli Study of Ovarian Cancer.
    • Gynecol Oncol. 2019 May;153(2):320-325. doi: 10.1016/j.ygyno.2019.02.022. Epub 2019 Mar 11.
    • Non-BRCA1/2 Variants Detected in a High-Risk Chilean Cohort With a History of Breast and/or Ovarian Cancer.
    • Adaniel C, Salinas F, Donaire JM, Bravo ME, Peralta O, Paredes H, Aliaga N, Sola A, Neira P, Behnke C, Rodriguez T, Torres S, Lopez F, Hurtado C.
    • J Glob Oncol. 2019 May;(5):1-14. doi: 10.1200/JGO.18.00163.
    • Multigene panel testing in unselected Israeli breast cancer cases: mutational spectrum and use of BRCA1/2 mutation prediction algorithms.
    • Bernstein-Molho R, Singer A, Laitman Y, Netzer I, Zalmanoviz S, Friedman E.
    • Breast Cancer Res Treat. 2019 Apr 12. doi: 10.1007/s10549-019-05228-6. [Epub ahead of print]
    • 23andMe DTC Breast and Ovarian Cancer Risk Test Misses Almost 90 Percent of BRCA Mutation Carriers.
    • Karow J.
    • Precision Oncology News. 2019 Apr 5.
    • Family history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk.
    • Hamada T, Yuan C, Yurgelun MB, Perez K, Khalaf N, Morales-Oyarvide V, Babic A, Nowak JA, Rubinson DA, Giannakis M, Ng K, Kraft P, Stampfer MJ, Giovannucci EL, Fuchs CS, Ogino S, Wolpin BM.
    • Br J Cancer. 2019 Apr;120(8):848-854. doi: 10.1038/s41416-019-0426-5. Epub 2019 Mar 14.
    • The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis.
    • Oh M, Alkhushaym N, Fallatah S, Althaghfi A, Aljadeed R, Alsowaida Y, Jeter J, Martin JR, Babiker HM, McBride A, Abraham I.
    • Prostate. 2019 Mar 22. doi: 10.1002/pros.23795. [Epub ahead of print]
    • Meta-Analysis
    • Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
    • Frey MK, Kopparam RV, Ni Zhou Z, Fields JC, Buskwofie A, Carlson AD, Caputo T, Holcomb K, Chapman-Davis E.
    • Cancer. 2019 Mar 1;125(5):690-697. doi: 10.1002/cncr.31856. Epub 2018 Nov 27.
    • Uterine cancer in Jewish Israeli BRCA1/2 mutation carriers.
    • Laitman Y, Michaelson-Cohen R, Levi E, Chen-Shtoyerman R, Reish O, Josefsberg Ben-Yehoshua S, Bernstein-Molho R, Keinan-Boker L, Rosengarten O, Silverman BG, Perri T, Korach J, Mor P, Ephrat Ben-Baruch N, Levy Lahad E, Friedman E; Israeli Consortium of Hereditary Breast Cancer.
    • Cancer. 2019 Mar 1;125(5):698-703. doi: 10.1002/cncr.31842. Epub 2018 Nov 29.
    • [BRCAmutations more frequent in people of Jewish ancestry].
    • Menko FH, Rosenberg EH, van der Kolk LE.
    • Ned Tijdschr Geneeskd. 2019 Mar 1;163. pii: D3663.
    • Review, [Article in Dutch]
    • The influence of BRCA variants of unknown significance on cancer risk management decision-making.
    • Chern JY, Lee SS, Frey MK, Lee J, Blank SV.
    • J Gynecol Oncol. 2019 Feb 27. doi: 10.3802/jgo.2019.30.e60. [Epub ahead of print]

    Editorial:

    Clinical significance of variants of unknown significances in BRCA genes.

    • A Pragmatic Testing-Eligibility Framework for Population Mutation Screening: The Example of BRCA1/2.
    • Best AF, Tucker MA, Frone MN, Greene MH, Peters JA, Katki HA.
    • Cancer Epidemiol Biomarkers Prev. 2019 Feb;28(2):293-302. doi: 10.1158/1055-9965.EPI-18-0584. Epub 2019 Jan 28.
    • The Role of BRCA Testing in Hereditary Pancreatic and Prostate Cancer Families.
    • Pilarski R.
    • Am Soc Clin Oncol Educ Book. 2019 Jan;(39):79-86. doi: 10.1200/EDBK_238977.
    • The rate of the recurrent MSH6 mutations in Ashkenazi Jewish breast cancer patients.
    • Bernstein-Molho R, Laitman Y, Schayek H, Iomdin S, Friedman E.
    • Cancer Causes Control. 2019 Jan;30(1):97-101. doi: 10.1007/s10552-018-1106-0. Epub 2018 Nov 30.
    • Cancer Susceptibility Genetic Testing in a High-Risk Cohort of Urban Ashkenazi Jewish Individuals.
    • Nielsen SM, De Simone LM, Olopade OI.
    • J Genet Couns. 2018 Dec;27(6):1405-1410. doi: 10.1007/s10897-018-0269-x. Epub 2018 Jun 26.
    • Population Based Testing for Primary Prevention: A Systematic Review.
    • Manchanda R, Gaba F.
    • Cancers (Basel). 2018 Nov 5;10(11). pii: E424. doi: 10.3390/cancers10110424.
    • The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations.
    • Barnes-Kedar I, Bernstein-Molho R, Ginzach N, Hartmajer S, Shapira T, Magal N, Kalis ML, Peretz T, Shohat M, Basel-Salmon L, Friedman E, Bazak L, Goldberg Y.
    • Breast Cancer Res Treat. 2018 Nov;172(1):151-157. doi: 10.1007/s10549-018-4887-7. Epub 2018 Jul 16.
    • Familial communication and cascade testing among relatives of BRCA population screening participants.
    • Lieberman S, Lahad A, Tomer A, Koka S, BenUziyahu M, Raz A, Levy-Lahad E.
    • Genet Med. 2018 Nov;20(11):1446-1454. doi: 10.1038/gim.2018.26. Epub 2018 Mar 29.
    • Hereditary cancer screening: Case reports and review of literature on ten Ashkenazi Jewish founder mutations.
    • Cox DM, Nelson KL, Clytone M, Collins DL.
    • Mol Genet Genomic Med. 2018 Nov;6(6):1236-1242. doi: 10.1002/mgg3.460. Epub 2018 Aug 27.
    • Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing.
    • Slavin TP, Banks KC, Chudova D, Oxnard GR, Odegaard JI, Nagy RJ, Tsang KWK, Neuhausen SL, Gray SW, Cristofanilli M, Rodriguez AA, Bardia A, Leyland-Jones B, Janicek MF, Lilly M, Sonpavde G, Lee CE, Lanman RB, Meric-Bernstam F, Kurzrock R, Weitzel JN.
    • J Clin Oncol. 2018 Oct 19:JCO1800328. doi: 10.1200/JCO.18.00328. [Epub ahead of print]
    • Prospective Study of Cancer Genetic Variants: Variation in Rate of Reclassification by Ancestry.
    • Slavin TP, Van Tongeren LR, Behrendt CE, Solomon I, Rybak C, Nehoray B, Kuzmich L, Niell-Swiller M, Blazer KR, Tao S, Yang K, Culver JO, Sand S, Castillo D, Herzog J, Gray SW, Weitzel JN.
    • J Natl Cancer Inst. 2018 Oct 1;110(10):1059-1066. doi: 10.1093/jnci/djy027.

    Introductory article, Editorial:

    The Ancestral Pace of Variant Reclassification.

    Full text: Prospective Study of Cancer Genetic Variants — Variation in Rate of Reclassification by Ancestry (Medscape Oncology)

    • Comparison of gynecologic cancer risk factors, incidence and mortality trends between South Korea and Israel, 1999-2013.
    • Michaan N, Park SY, Won YJ, Lim MC.
    • Jpn J Clin Oncol. 2018 Oct 1;48(10):884-891. doi: 10.1093/jjco/hyy111.
    • BRCA1 and BRCA2 Mutations Other Than the Founder Alleles Among Ashkenazi Jewish in the Population of Argentina.
    • Solano AR, Liria NC, Jalil FS, Faggionato DM, Mele PG, Mampel A, Cardoso FC, Podesta EJ.
    • Front Oncol. 2018 Aug 21;8:323. doi: 10.3389/fonc.2018.00323. eCollection 2018.
    • Accuracy of Risk Prediction Models for Breast Cancer and BRCA1/BRCA2 Mutation Carrier Probabilities in Israel.
    • Kenan ES, Friger M, Shochat-Bigon D, Schayek H, Bernstein-Molho R, Friedman E.
    • Anticancer Res. 2018 Aug;38(8):4557-4563. doi: 10.21873/anticanres.12760.
    • “Second-Class Status?” Insight into Communication Patterns and Common Concerns Among Men with Hereditary Breast and Ovarian Cancer Syndrome.
    • Suttman A, Pilarski R, Agnese DM, Senter L.
    • J Genet Couns. 2018 Aug;27(4):885-893. doi: 10.1007/s10897-018-0214-z. Epub 2018 Feb 5.
    • Current detection rates and time-to-detection of all identifiable BRCA carriers in the Greater London population.
    • Manchanda R, Blyuss O, Gaba F, Gordeev VS, Jacobs C, Burnell M, Gan C, Taylor R, Turnbull C, Legood R, Zaikin A, Antoniou AC, Menon U, Jacobs I.
    • J Med Genet. 2018 Aug;55(8):538-545. doi: 10.1136/jmedgenet-2017-105195. Epub 2018 Apr 5.
    • Mutational analysis of candidate genes in Israeli male breast cancer cases.
    • Schayek H, Korach H, Laitman Y, Bernstein-Molho R, Friedman E.
    • Breast Cancer Res Treat. 2018 Jul;170(2):399-404. doi: 10.1007/s10549-018-4765-3. Epub 2018 Mar 21.
    • Impact of BRCA mutations on outcomes among patients with serous endometrial cancer.
    • Kadan Y, Raviv O, Segev Y, Lavie O, Bruchim I, Fishman A, Michaelson R, Beller U, Helpman L.
    • Int J Gynaecol Obstet. 2018 Jul;142(1):91-96. doi: 10.1002/ijgo.12486. Epub 2018 Apr 2.
    • Evaluation of some direct-to-consumer genetic testing reveals inaccuracies and misinterpretations.
    • [No author given]
    • FORCE. XRAYS. 2018 Jun 28.

    False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care.

    • Direct-to-Consumer Genetic Testing: The Implications of the US FDA's First Marketing Authorization for BRCA Mutation Testing.
    • Gill J, Obley AJ, Prasad V.
    • JAMA. 2018 Jun 19;319(23):2377-2378. doi: 10.1001/jama.2018.5330.
    • Commentary
    • XRAYS Follow Up: Does expanded genetic testing benefit Jewish women with breast cancer?
    • [No author given]
    • FORCE. XRAYS. 2018 Jun 7.

    Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.

    Research review, Commentary: Does expanded genetic testing benefit Jewish women diagnosed with breast cancer? (FORCE. XRAYS. 2017 Sep 13.)

    • Malignant Abnormalities in Male BRCA Mutation Carriers: Results From a Prospectively Screened Cohort.
    • Mano R, Tamir S, Kedar I, Benjaminov O, Baniel J, Tabachnik T, Margel D.
    • JAMA Oncol. 2018 Jun 1;4(6):872-874. doi: 10.1001/jamaoncol.2018.0271.
    • Testing Ashkenazi Jewish Women for Mutations Predisposing to Breast Cancer in Genes Other Than BRCA1 and BRCA2.
    • Narod S, Sopik V, Cybulski C.
    • JAMA Oncol. 2018 May 3. doi: 10.1001/jamaoncol.2018.0595. [Epub ahead of print]
    • Letter

    Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.

    Letter, Reply:

    Testing Ashkenazi Jewish Women for Mutations Predisposing to Breast Cancer in Genes Other Than BRCA1 and BRCA2—Reply.

    • The Relationship Between Body Image, Gender, Subjective Norms, and the Decision to Undergo Preventive Mastectomy Among Arab and Jewish BRCA Carriers.
    • Kardosh M, Bar-Tal Y, Barnoy S.
    • Cancer Nurs. 2018 May/Jun;41(3):255-262. doi: 10.1097/NCC.0000000000000503.
    • Direct-to-Consumer Test for BRCA Mutations Authorized.
    • [No authors listed]
    • Cancer Discov. 2018 May;8(5):OF5. doi: 10.1158/2159-8290.CD-NB2018-031. Epub 2018 Mar 14.
    • News
    • Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations.
    • Rebbeck TR, Friebel TM, Friedman E, Hamann U, Huo D, Kwong A, Olah E, Olopade OI, Solano AR, Teo SH, Thomassen M, Weitzel JN, Chan TL, Couch FJ, Goldgar DE, Kruse TA, Palmero EI, Park SK, Torres D, van Rensburg EJ, McGuffog L, Parsons MT, Leslie G, Aalfs CM, Abugattas J, Adlard J, Agata S, Aittomäki K, Andrews L, Andrulis IL, Arason A, Arnold N, Arun BK, Asseryanis E, Auerbach L, Azzollini J, Balmaña J, Barile M, Barkardottir RB, Barrowdale D, Benitez J, Berger A, Berger R, Blanco AM, Blazer KR, Blok MJ, Bonadona V, Bonanni B, Bradbury AR, Brewer C, Buecher B, Buys SS, Caldes T, Caliebe A, Caligo MA, Campbell I, Caputo SM, Chiquette J, Chung WK, Claes KBM, Collée JM, Cook J, Davidson R, de la Hoya M, De Leeneer K, de Pauw A, Delnatte C, Diez O, Ding YC, Ditsch N, Domchek SM, Dorfling CM, Velazquez C, Dworniczak B, Eason J, Easton DF, Eeles R, Ehrencrona H, Ejlertsen B; EMBRACE, Engel C, Engert S, Evans DG, Faivre L, Feliubadaló L, Ferrer SF, Foretova L, Fowler J, Frost D, Galvão HCR, Ganz PA, Garber J, Gauthier-Villars M, Gehrig A; GEMO Study Collaborators, Gerdes AM, Gesta P, Giannini G, Giraud S, Glendon G, Godwin AK, Greene MH, Gronwald J, Gutierrez-Barrera A, Hahnen E, Hauke J; HEBON, Henderson A, Hentschel J, Hogervorst FBL, Honisch E, Imyanitov EN, Isaacs C, Izatt L, Izquierdo A, Jakubowska A, James P, Janavicius R, Jensen UB, John EM, Vijai J, Kaczmarek K, Karlan BY, Kast K, Investigators K, Kim SW, Konstantopoulou I, Korach J, Laitman Y, Lasa A, Lasset C, Lázaro C, Lee A, Lee MH, Lester J, Lesueur F, Liljegren A, Lindor NM, Longy M, Loud JT, Lu KH, Lubinski J, Machackova E, Manoukian S, Mari V, Martínez-Bouzas C, Matrai Z, Mebirouk N, Meijers-Heijboer HEJ, Meindl A, Mensenkamp AR, Mickys U, Miller A, Montagna M, Moysich KB, Mulligan AM, Musinsky J, Neuhausen SL, Nevanlinna H, Ngeow J, Nguyen HP, Niederacher D, Nielsen HR, Nielsen FC, Nussbaum RL, Offit K, Öfverholm A, Ong KR, Osorio A, Papi L, Papp J, Pasini B, Pedersen IS, Peixoto A, Peruga N, Peterlongo P, Pohl E, Pradhan N, Prajzendanc K, Prieur F, Pujol P, Radice P, Ramus SJ, Rantala J, Rashid MU, Rhiem K, Robson M, Rodriguez GC, Rogers MT, Rudaitis V, Schmidt AY, Schmutzler RK, Senter L, Shah PD, Sharma P, Side LE, Simard J, Singer CF, Skytte AB, Slavin TP, Snape K, Sobol H, Southey M, Steele L, Steinemann D, Sukiennicki G, Sutter C, Szabo CI, Tan YY, Teixeira MR, Terry MB, Teulé A, Thomas A, Thull DL, Tischkowitz M, Tognazzo S, Toland AE, Topka S, Trainer AH, Tung N, van Asperen CJ, van der Hout AH, van der Kolk LE, van der Luijt RB, Van Heetvelde M, Varesco L, Varon-Mateeva R, Vega A, Villarreal-Garza C, von Wachenfeldt A, Walker L, Wang-Gohrke S, Wappenschmidt B, Weber BHF, Yannoukakos D, Yoon SY, Zanzottera C, Zidan J, Zorn KK, Hutten Selkirk CG, Hulick PJ, Chenevix-Trench G, Spurdle AB, Antoniou AC, Nathanson KL.
    • Hum Mutat. 2018 May;39(5):593-620. doi: 10.1002/humu.23406. Epub 2018 Mar 12.
    • False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care.
    • Tandy-Connor S, Guiltinan J, Krempely K, LaDuca H, Reineke P, Gutierrez S, Gray P, Tippin Davis B.
    • Genet Med. 2018 Mar 22. doi: 10.1038/gim.2018.38. [Epub ahead of print]

    Commentary:

    Attention: Direct-To-Consumer patrons: Proceed with caution.

    Research news: Evaluation of some direct-to-consumer genetic testing reveals inaccuracies and misinterpretations (FORCE. XRAYS.)

    Press: Wrangle Over DTC Results—Ambry Study Highlights 40% False Positives, 23andMe Defends Tests, and Experts Weigh In. (Clinical OMICs)

    Press: Ambry and My Gene Counsel Team Up on Tests to Confirm DTC Results, Counseling. (Clinical OMICs)

    • FDA approves breast cancer test kits: how useful are they?
    • [No author given]
    • FORCE. XRAYS. 2018 Mar 19.

    FDA News Release: FDA authorizes, with special controls, direct-to-consumer test that reports three mutations in the BRCA breast cancer genes (U.S. Food & Drug Administration)

    Press: Oncology Community Sees Potential for Patient Harm in FDA OK of 23andMe BRCA Test (GenomeWeb)

    Press: FDA Authorizes 23andMe DTC Test Report for Three BRCA Mutations (GenomeWeb)

    • Medical Strategy or Marketing Strategy?
    • Resta R.
    • The DNA Exchange. 2018 Mar 18.
    • First DTC Test for Some BRCA Mutations Authorized by FDA.
    • Nelson R.
    • Medscape. Medscape Medical News. 2018 Mar 7.
    • FDA authorizes, with special controls, direct-to-consumer test that reports three mutations in the BRCA breast cancer genes.
    • [No author given]
    • U.S. Food & Drug Administration. FDA News Release. 2018 Mar 6.

    Blog post, News: NSGC Responds to U.S. Food and Drug Administration Approval of Direct-to-Consumer Cancer Test that Reports Three BRCA Mutations (NSGC Blog)

    News: FDA approves breast cancer test kits: how useful are they? (FORCE. XRAYS)

    • BRCA1 mutation spectrum, functions, and therapeutic strategies: The story so far.
    • Sharma B, Preet Kaur R, Raut S, Munshi A.
    • Curr Probl Cancer. 2018 Mar - Apr;42(2):189-207. doi: 10.1016/j.currproblcancer.2018.01.001. Epub 2018 Jan 8.
    • Review
    • Phenotypic characteristics of colorectal cancer in BRCA1/2 mutation carriers.
    • Grinshpun A, Halpern N, Granit RZ, Hubert A, Hamburger T, Laitman Y, Shacham-Shmueli E, Peerless Y, Friedman E, Peretz T.
    • Eur J Hum Genet. 2018 Mar;26(3):382-386. doi: 10.1038/s41431-017-0067-1. Epub 2018 Jan 10.
    • Population-Based Genetic Testing for BRCA1 and BRCA2.
    • Narod S, Akbari MR.
    • J Clin Oncol. 2018 Feb 10;36(5):517. doi: 10.1200/JCO.2017.75.8490. Epub 2018 Jan 2.
    • Letter

    Editorial:

    Genetic Testing: What Problem Are We Trying to Solve?

    National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer.

    Letter, Comment:

    Reply to S. Nakamura et al and S. Narod et al.

    • The yield of targeted genotyping for the recurring mutations in BRCA1/2 in Israel.
    • Bernstein-Molho R, Laitman Y, Schayek H, Reish O, Lotan S, Haim S, Zidan J, Friedman E.
    • Breast Cancer Res Treat. 2018 Feb;167(3):697-702. doi: 10.1007/s10549-017-4551-7. Epub 2017 Oct 30.
    • Reflex Testing for Germline BRCA1, BRCA2, PALB2, and ATM Mutations in Pancreatic Cancer: Mutation Prevalence and Clinical Outcomes From Two Canadian Research Registries.
    • Smith AL, Wong C, Cuggia A, Borgida A, Holter S, Hall A, Connor AA, Bascuñana C, Asselah J, Bouganim N, Poulin V, Jolivet J, Vafiadis P, Le P, Martel G, Lemay F, Beaudoin A, Rafatzand K, Chaudhury P, Barkun J, Metrakos P, Marcus V, Omeroglu A, Chong G, Akbari MR, Foulkes WD, Gallinger S, Zogopoulos G.
    • JCO Precis Oncol. 2018 Nov [Epub 2018 Jan 19];2:1-16. doi: 10.1200/PO.17.00098.

    Editorial:

    Should We Lower Our Threshold for Germline Genetic Assessment in Pancreatic Adenocarcinoma?

    • Abnormal Findings Detected by Multi-modality Breast Imaging and Biopsy Results in a High-risk Clinic.
    • Laitman Y, Feldman DM, Sklair-Levy M, Yosepovich A, Barshack-Nakar I, Brodsky M, Halshtok O, Shalmon A, Gotlieb M, Friedman E.
    • Clin Breast Cancer. 2017 Dec 11. pii: S1526-8209(17)30559-1. doi: 10.1016/j.clbc.2017.12.005. [Epub ahead of print]
    • Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
    • Walsh T, Mandell JB, Norquist BM, Casadei S, Gulsuner S, Lee MK, King MC.
    • JAMA Oncol. 2017 Dec 1;3(12):1647-1653. doi: 10.1001/jamaoncol.2017.1996.

    Audio Interview: Breast Cancer Due to Non–BRCA1 and Non–BRCA2 Mutations in Ashkenazi Jewish Women. (The JAMA Network)

    Letter:

    Testing Ashkenazi Jewish Women for Mutations Predisposing to Breast Cancer in Genes Other Than BRCA1 and BRCA2

    Letter, Reply:

    Testing Ashkenazi Jewish Women for Mutations Predisposing to Breast Cancer in Genes Other Than BRCA1 and BRCA2—Reply

    Research review, Commentary: Does expanded genetic testing benefit Jewish women diagnosed with breast cancer? (FORCE. XRAYS. 2017 Sep 13.)

    Research review, Commentary: XRAYS Follow Up: Does expanded genetic testing benefit Jewish women with breast cancer? (FORCE. XRAYS. 2018 Jun 7.)

    • Clinical testing with a panel of 25 genes associated with increased cancer risk results in a significant increase in clinically significant findings across a broad range of cancer histories.
    • Rosenthal ET, Bernhisel R, Brown K, Kidd J, Manley S.
    • Cancer Genet. 2017 Dec;218-219:58-68. doi: 10.1016/j.cancergen.2017.09.003. Epub 2017 Sep 25.
    • Is there a difference in testosterone levels and its regulators in men carrying BRCA mutations?
    • Goldberg H, Grievink LS, Mano R, Ber Y, Ozalbo R, Tuval S, Baniel J, Margel D.
    • Oncotarget. 2017 Oct 10;8(61):103843-103850. doi: 10.18632/oncotarget.21802. eCollection 2017 Nov 28.
    • Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry.
    • Manchanda R, Patel S, Antoniou AC, Levy-Lahad E, Turnbull C, Evans G, Hopper J, Macinnis RJ, Menon U, Jacobs I, Legood R.
    • Am J Obstet Gynecol. 2017 Nov;217(5):578.e1-578.e12. doi: 10.1016/j.ajog.2017.06.038. Epub 2017 Jul 6.
    • Early onset breast cancer in Ashkenazi women carriers of founder BRCA1/2 mutations: beyond 10 years of follow-up.
    • Dagan E, Gershoni-Baruch R, Kurolap A, Fried G.
    • Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12594. Epub 2016 Oct 10.
    • BRCA1/BRCA2 mutations in a Mediterranean population (Apulia Region) with breast or ovarian cancer: a single center experience.
    • Caloro M, Orlando L, Lutrino ES, Quaranta A, Caliolo C, Schiavone P, Aprile G, Chetrì MC, D'Amico M, Rizzo P, Fedele P, Loparco D, Mazzoni E, Marino A, Calvani N, Sponziello F, Nacci A, Cinefra M, Ferrara P, Cinieri S.
    • Ann Oncol. 2017 Oct;28 Suppl 6:vi32. doi: 10.1093/annonc/mdx424.025.
    • Impact of Sixteen Established Pancreatic Cancer Susceptibility Loci in American Jews.
    • Streicher SA, Klein AP, Olson SH, Amundadottir LT, DeWan AT, Zhao H, Risch HA.
    • Cancer Epidemiol Biomarkers Prev. 2017 Oct;26(10):1540-1548. doi: 10.1158/1055-9965.EPI-17-0262. Epub 2017 Jul 28.
    • Identification of pathogenic retrotransposon insertions in cancer predisposition genes.
    • Qian Y, Mancini-DiNardo D, Judkins T, Cox HC, Brown K, Elias M, Singh N, Daniels C, Holladay J, Coffee B, Bowles KR, Roa BB.
    • Cancer Genet. 2017 Oct;216-217:159-169. doi: 10.1016/j.cancergen.2017.08.002. Epub 2017 Aug 24.
    • Performing and Declining PGD: Accounts of Jewish Israeli Women Who Carry a BRCA1/2 Mutation or Partners of Male Mutation Carriers.
    • Dagan E, Birenbaum-Carmeli D, Friedman E, Feldman B.
    • J Genet Couns. 2017 Oct;26(5):1070-1079. doi: 10.1007/s10897-017-0087-6. Epub 2017 Mar 6.
    • The Impact of Mental Illness on Uptake of Genetic Counseling for Hereditary Breast Cancer and Ovarian Cancer in a Multiethnic Cohort of Breast Cancer Patients.
    • Ackerman MG, Shapiro PA, Coe A, Trivedi MS, Crew KD.
    • Breast J. 2017 Sep;23(5):519-524. doi: 10.1111/tbj.12791. Epub 2017 Mar 21.
    • Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates.
    • Helpman L, Zidan O, Friedman E, Kalfon S, Perri T, Ben-Baruch G, Korach J.
    • J Gynecol Oncol. 2017 Sep;28(5):e61. doi: 10.3802/jgo.2017.28.e61. Epub 2017 Jun 5.
    • Frequency of Germline BRCA1/2 Mutations in Unselected Patients With Colorectal Cancer.
    • Daniels MS, Bannon SA, Mork ME.
    • J Clin Oncol. 2017 Aug 1;35(22):2588. doi: 10.1200/JCO.2017.72.7222. Epub 2017 May 16.

    Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer.

    Letter, Reply:

    Reply to M.S. Daniels et al.

    • Population screening for BRCA1/BRCA2 founder mutations in Ashkenazi Jews: proactive recruitment compared with self-referral.
    • Lieberman S, Tomer A, Ben-Chetrit A, Olsha O, Strano S, Beeri R, Koka S, Fridman H, Djemal K, Glick I, Zalut T, Segev S, Sklair M, Kaufman B, Lahad A, Raz A, Levy-Lahad E.
    • Genet Med. 2017 Jul;19(7):754-762. doi: 10.1038/gim.2016.182. Epub 2016 Dec 8.
    • Multigene panels in Ashkenazi Jewish patients yield high rates of actionable mutations in multiple non-BRCA cancer-associated genes.
    • Frey MK, Sandler G, Sobolev R, Kim SH, Chambers R, Bassett RY, Martineau J, Sapra KJ, Boyd L, Curtin JP, Pothuri B, Blank SV.
    • Gynecol Oncol. 2017 Jul;146(1):123-128. doi: 10.1016/j.ygyno.2017.04.009. Epub 2017 May 8.
    • Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients.
    • Crawford B, Adams SB, Sittler T, van den Akker J, Chan S, Leitner O, Ryan L, Gil E, van 't Veer L.
    • Breast Cancer Res Treat. 2017 Jun;163(2):383-390. doi: 10.1007/s10549-017-4181-0. Epub 2017 Mar 9.
    • Population screening for BRCA1/BRCA2 mutations: lessons from qualitative analysis of the screening experience.
    • Lieberman S, Lahad A, Tomer A, Cohen C, Levy-Lahad E, Raz A.
    • Genet Med. 2017 Jun;19(6):628-634. doi: 10.1038/gim.2016.175. Epub 2016 Dec 1.
    • Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer.
    • Halpern N, Sonnenblick A, Uziely B, Divinsky L, Goldberg Y, Hamburger T, Peretz T, Kadouri L.
    • Int J Cancer. 2017 May 1;140(9):2145-2149. doi: 10.1002/ijc.30616. Epub 2017 Feb 8.
    • Population-Based Study of Attitudes toward BRCA Genetic Testing among Orthodox Jewish Women.
    • Tang EY, Trivedi MS, Kukufka R, Chung WK, David R, Respler L, Leifer S, Schechter I, Crew KD.
    • Breast J. 2017 May;23(3):333-337. doi: 10.1111/tbj.12736. Epub 2016 Nov 30.
    • Experiences from a pilot program bringing BRCA1/2 genetic screening to theUS Ashkenazi Jewish population.
    • Wiesman C, Rose E, Grant A, Zimilover A, Klugman S, Schreiber-Agus N.
    • Genet Med. 2017 May;19(5):529-536. doi: 10.1038/gim.2016.154. Epub 2016 Oct 13.

    Press: New Study Highlights the Benefits of BRCA Testing for All People of Ashkenazi Jewish Descent. (Newswise, Montefiore Health System)

    • Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer.
    • Yurgelun MB, Kulke MH, Fuchs CS, Allen BA, Uno H, Hornick JL, Ukaegbu CI, Brais LK, McNamara PG, Mayer RJ, Schrag D, Meyerhardt JA, Ng K, Kidd J, Singh N, Hartman AR, Wenstrup RJ, Syngal S.
    • J Clin Oncol. 2017 Apr 1;35(10):1086-1095. doi: 10.1200/JCO.2016.71.0012. Epub 2017 Jan 30.

    Letter, Comments:

    Frequency of Germline BRCA1/2 Mutations in Unselected Patients With Colorectal Cancer.

    Letter, Reply:

    Reply to M.S. Daniels et al.

    • The experience of women carriers of BRCA mutations following risk-reducing surgery: A cultural perspective.
    • Mahat-Shamir M, Possick C.
    • Health Care Women Int. 2017 Apr;38(4):344-360. doi: 10.1080/07399332.2016.1267182. Epub 2016 Dec 7.
    • Orthodox Jewish Thought Leaders' Insights Regarding BRCA Mutations: A Descriptive Study.
    • Bressler T, Popp B.
    • J Oncol Pract. 2017 Apr;13(4):e303-e309. doi: 10.1200/JOP.2016.015503. Epub 2016 Nov 22.
    • Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: A meta-analysis and case report.
    • de Jonge MM, Mooyaart AL, Vreeswijk MP, de Kroon CD, van Wezel T, van Asperen CJ, Smit VT, Dekkers OM, Bosse T.
    • Eur J Cancer. 2017 Feb;72:215-225. doi: 10.1016/j.ejca.2016.11.028. Epub 2016 Dec 31.
    • Review
    • Cancer Risk Information Sharing: The Experience of Individuals Receiving Genetic Counseling for BRCA1/2 Mutations.
    • Chopra I, Kelly KM.
    • J Health Commun. 2017 Feb;22(2):143-152. doi: 10.1080/10810730.2016.1258743. Epub 2017 Jan 23.
    • Community attitudes towards a Jewish community BRCA1/2 testing program.
    • Cousens N, Kaur R, Meiser B, Andrews L.
    • Fam Cancer. 2017 Jan;16(1):17-28. doi: 10.1007/s10689-016-9918-0.
    • Multi-gene panel testing for hereditary cancer susceptibility in a rural Familial Cancer Program.
    • Hermel DJ, McKinnon WC, Wood ME, Greenblatt MS.
    • Fam Cancer. 2017 Jan;16(1):159-166. doi: 10.1007/s10689-016-9913-5.

    Letter:

    Patients with negative multi-gene panel testing: a back to the future paradox?

    Letter:

    Placing negative multi-gene panel results into clinical context.

    • Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women.
    • Rebbeck TR, Friebel TM, Mitra N, Wan F, Chen S, Andrulis IL, Apostolou P, Arnold N, Arun BK, Barrowdale D, Benitez J, Berger R, Berthet P, Borg A, Buys SS, Caldes T, Carter J, Chiquette J, Claes KB, Couch FJ, Cybulski C, Daly MB, de la Hoya M, Diez O, Domchek SM, Nathanson KL, Durda K, Ellis S; EMBRACE, Evans DG, Foretova L, Friedman E, Frost D, Ganz PA, Garber J, Glendon G, Godwin AK, Greene MH, Gronwald J, Hahnen E, Hallberg E, Hamann U, Hansen TV; HEBON, Imyanitov EN, Isaacs C, Jakubowska A, Janavicius R, Jaworska-Bieniek K, John EM, Karlan BY, Kaufman B, Investigators K, Kwong A, Laitman Y, Lasset C, Lazaro C, Lester J, Loman N, Lubinski J, Manoukian S, Mitchell G, Montagna M, Neuhausen SL, Nevanlinna H, Niederacher D, Nussbaum RL, Offit K, Olah E, Olopade OI, Park SK, Piedmonte M, Radice P, Rappaport-Fuerhauser C, Rookus MA, Seynaeve C, Simard J, Singer CF, Soucy P, Southey M, Stoppa-Lyonnet D, Sukiennicki G, Szabo CI, Tancredi M, Teixeira MR, Teo SH, Terry MB, Thomassen M, Tihomirova L, Tischkowitz M, Toland AE, Toloczko-Grabarek A, Tung N, van Rensburg EJ, Villano D, Wang-Gohrke S, Wappenschmidt B, Weitzel JN, Zidan J, Zorn KK, McGuffog L, Easton D, Chenevix-Trench G, Antoniou AC, Ramus SJ.
    • Breast Cancer Res. 2016 Nov 11;18(1):112.

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: BRCA2 and PALB2 mutation

    • Earlier Age of Breast Cancer Onset in Israeli BRCA Carriers-Is it a Real Phenomenon?
    • Agranat S, Baris H, Kedar I, Shochat M, Rizel S, Perry S, Margel D, Sulkes A, Yerushalmi R.
    • Breast J. 2016 Nov;22(6):662-666. doi: 10.1111/tbj.12653. Epub 2016 Aug 17.
    • A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer.
    • Vijai J, Topka S, Villano D, Ravichandran V, Maxwell KN, Maria A, Thomas T, Gaddam P, Lincoln A, Kazzaz S, Wenz B, Carmi S, Schrader KA, Hart SN, Lipkin SM, Neuhausen SL, Walsh MF, Zhang L, Lejbkowicz F, Rennert H, Stadler ZK, Robson M, Weitzel JN, Daly MJ, Couch FJ, Nathanson KL, Norton L, Rennert G, Offit K.
    • Cancer Discov. 2016 Nov;6(11):1267-1275. Epub 2016 Sep 21.
    • Automated Breast Volumetric Sonography Compared with Magnetic Resonance Imaging in Jewish BRCA 1/2 Mutation Carriers.
    • Halshtok Neiman O, Erlich Z, Friedman E, Rundstein A, Shalmon A, Servadio Y, Sklair Levy M.
    • Isr Med Assoc J. 2016 Oct;18(10):609-612.
    • Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?
    • Teo MY, O'Reilly EM.
    • J Gastrointest Oncol. 2016 Oct;7(5):738-749.
    • Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis.
    • Baretta Z, Mocellin S, Goldin E, Olopade OI, Huo D.
    • Medicine (Baltimore). 2016 Oct;95(40):e4975.
    • A Dedicated Follow-Up Clinic for BRCA Mutation Carriers.
    • Yerushalmi R, Rizel S, Zoref D, Sharon E, Eitan R, Sabah G, Grubstein A, Rafson Y, Cohen M, Magen A, Birenboim I, Margel D, Ozlavo R, Sulkes A, Brenner B, Perry S.
    • Isr Med Assoc J. 2016 Sep;18(9):549-552.

    Editorial:

    Handling Individuals with High Cancer Risk: One Size Doesn't Fit All.

    • Cluster-randomised non-inferiority trial comparing DVD-assisted and traditional genetic counselling in systematic population testing for BRCA1/2 mutations.
    • Manchanda R, Burnell M, Loggenberg K, Desai R, Wardle J, Sanderson SC, Gessler S, Side L, Balogun N, Kumar A, Dorkins H, Wallis Y, Chapman C, Tomlinson I, Taylor R, Jacobs C, Legood R, Raikou M, McGuire A, Beller U, Menon U, Jacobs I.
    • J Med Genet. 2016 Jul;53(7):472-80. doi: 10.1136/jmedgenet-2015-103740. Epub 2016 Mar 18.
    • Population-Based BRCA1/2 Testing in Ashkenazi Jews: Ready for Prime Time.
    • Lynce F, Isaacs C.
    • J Natl Compr Canc Netw. 2016 Jun;14(6):809-12.
    • Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.
    • Tung N, Lin NU, Kidd J, Allen BA, Singh N, Wenstrup RJ, Hartman AR, Winer EP, Garber JE.
    • J Clin Oncol. 2016 May 1;34(13):1460-8. doi: 10.1200/JCO.2015.65.0747. Epub 2016 Mar 14.

    Letter

    Next-Generation Sequencing of Tumors to Better Estimate the Clinical Significance of Non-BRCA Germline Deleterious Mutations.

    • Bad Luck Or Bad Genes? Dealing With BRCA And 'A Cancer In The Family'.
    • Terry Gross, Theodora Ross.
    • NPR. Fresh Air. Health. 2016 Mar 14.
    • Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant.
    • Schrader KA, Stratton KL, Murali R, Laitman Y, Cavallone L, Offit L, Wen YH, Thomas T, Shah S, Rau-Murthy R, Manschreck C, Salo-Mullen E, Otegbeye E, Corines M, Zhang L, Norton L, Hudis C, Klein RJ, Kauff ND, Robson M, Stadler ZK, Haber DA, Lipkin SM, Friedman E, Foulkes WD, Altshuler D, Vijai J, Offit K.
    • J Clin Oncol. 2016 Mar 10;34(8):e61-7. doi: 10.1200/JCO.2013.50.0272. Epub 2014 Jun 30.
    • The risk for developing cancer in Israeli ATM, BLM, and FANCC heterozygous mutation carriers.
    • Laitman Y, Boker-Keinan L, Berkenstadt M, Liphsitz I, Weissglas-Volkov D, Ries-Levavi L, Sarouk I, Pras E, Friedman E.
    • Cancer Genet. 2016 Mar;209(3):70-4. doi: 10.1016/j.cancergen.2015.12.006. Epub 2015 Dec 22.
    • Clinical and Pathological Characteristics of Incidental Diagnostic Early Occult Malignancy After Risk-Reducing Salpingo-Oophorectomy in BRCA Mutation Carriers.
    • Lavie O, Moskoviz MG, Auslender R, Gemer O, Bitterman A, Younes G, Segev Y.
    • Int J Gynecol Cancer. 2016 Feb;26(2):233-9. doi: 10.1097/IGC.0000000000000624.
    • Screening for germline mutations in breast/ovarian cancer susceptibility genes in high-risk families in Israel.
    • Yablonski-Peretz T, Paluch-Shimon S, Gutman LS, Kaplan Y, Dvir A, Barnes-Kedar I, Kadouri L, Semenisty V, Efrat N, Neiman V, Glasser Y, Michaelson-Cohen R, Katz L, Kaufman B, Golan T, Reish O, Hubert A, Safra T, Yaron Y, Friedman E.
    • Breast Cancer Res Treat. 2016 Jan;155(1):133-8. doi: 10.1007/s10549-015-3662-2. Epub 2015 Dec 19.
    • Genetic screening for gynecological cancer: where are we heading?
    • Manchanda R, Jacobs I.
    • Future Oncol. 2016 Jan;12(2):207-20. doi: 10.2217/fon.15.278. Epub 2015 Dec 7.
    • Editorial / Commentary
    • Identification of germline genetic mutations in patients with pancreatic cancer.
    • Salo-Mullen EE, O'Reilly EM, Kelsen DP, Ashraf AM, Lowery MA, Yu KH, Reidy DL, Epstein AS, Lincoln A, Saldia A, Jacobs LM, Rau-Murthy R, Zhang L, Kurtz RC, Saltz L, Offit K, Robson ME, Stadler ZK.
    • Cancer. 2015 Dec 15;121(24):4382-4388. doi: 10.1002/cncr.29664. Epub 2015 Oct 6.
    • The Roots of BRCA1 Mutations for Ashkenazi Jews.
    • C. Claiborne Ray.
    • NY Times. Science. 2015 Oct 12.
    • Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma.
    • Holter S, Borgida A, Dodd A, Grant R, Semotiuk K, Hedley D, Dhani N, Narod S, Akbari M, Moore M, Gallinger S.
    • J Clin Oncol. 2015 Oct 1;33(28):3124-9. doi: 10.1200/JCO.2014.59.7401. Epub 2015 May 4.

    Comment / Editorial

    Assessing the Significance of BRCA1 and BRCA2 Mutations in Pancreatic Cancer.

    • Genetic counseling content: How does it impact health behavior?
    • Kelly KM, Ellington L, Schoenberg N, Jackson T, Dickinson S, Porter K, Leventhal H, Andrykowski M.
    • J Behav Med. 2015 Oct;38(5):766-76. doi: 10.1007/s10865-014-9613-2. Epub 2014 Dec 23.
    • Screening for breast cancer by molecular testing for three founder mutations in the BRCA1 and BRCA2 genes among women of Ashkenazi Jewish heritage.
    • Palomaki GE.
    • J Med Screen. 2015 Sep;22(3):109-11. doi: 10.1177/0969141315579701. Epub 2015 May 5.
    • BRCA1/2 population screening: embracing the benefits.
    • Plon SE.
    • Curr Oncol. 2015 Aug;22(4):e230-1. doi: 10.3747/co.22.2660.

    Commentary

    Is it time to offer BRCA1 and BRCA2 testing to all Jewish women?

    • Is it time to offer BRCA1 and BRCA2 testing to all Jewish women?
    • Metcalfe KA, Eisen A, Lerner-Ellis J, Narod SA.
    • Curr Oncol. 2015 Aug;22(4):e233-6. doi: 10.3747/co.22.2527.
    • Testing helps fight ovarian, breast cancers—but not everyone agrees on how to do it.
    • Maria Delaney.
    • Ars Technica. 2015 Jul 1.
    • Survey on Addressing the Information and Support Needs of Jewish Women at Increased Risk for or Diagnosed with Breast Cancer: The Sharsheret Experience.
    • Tercyak KP, Silber E, Johnson AC, Fleischmann A, Murphy SE, Mays D, O'Neill SC, Sharkey CM, Shoretz R.
    • Healthcare (Basel). 2015 May 22;3(2):324-37. doi: 10.3390/healthcare3020324.
    • Genotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers.
    • Bayraktar S, Jackson M, Gutierrez-Barrera AM, Liu D, Meric-Bernstam F, Brandt A, Woodson A, Litton J, Lu KH, Valero V, Arun BK.
    • Breast J. 2015 May-Jun;21(3):260-7. doi: 10.1111/tbj.12392. Epub 2015 Mar 19.
    • Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers.
    • Perri T, Lifshitz D, Sadetzki S, Oberman B, Meirow D, Ben-Baruch G, Friedman E, Korach J.
    • Fertil Steril. 2015 May;103(5):1305-12. doi: 10.1016/j.fertnstert.2015.02.011. Epub 2015 Mar 16.
    • Cancer risks in Jewish male BRCA1 and BRCA2 mutation carriers.
    • Laitman Y, Keinan Boker L, Liphsitz I, Weissglas-Volkov D, Litz-Philipsborn S, Schayek H, Friedman E.
    • Breast Cancer Res Treat. 2015 Apr;150(3):631-5. doi: 10.1007/s10549-015-3340-4. Epub 2015 Mar 19.
    • To Reflex or Not: Additional BRCA1/2 Testing in Ashkenazi Jewish Individuals Without Founder Mutations.
    • Petrucelli N, Mange S, Fulbright JL, Dohany L, Zakalik D, Duquette D.
    • J Genet Couns. 2015 Apr;24(2):285-293. Epub 2014 Sep 9.
    • Lizzie Stark's ‘Real Steps to Survival’
    • Seth Berkman
    • The Sisterhood, 2015 Jan 6
    • Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.
    • Tung N, Battelli C, Allen B, Kaldate R, Bhatnagar S, Bowles K, Timms K, Garber JE, Herold C, Ellisen L, Krejdovsky J, DeLeonardis K, Sedgwick K, Soltis K, Roa B, Wenstrup RJ, Hartman A.
    • Cancer. 2015 Jan 1;121(1):25-33. doi: 10.1002/cncr.29010. Epub 2014 Sep 3.

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: Slides/Data from NSGC

    • Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.
    • Rosenthal E, Moyes K, Arnell C, Evans B, Wenstrup RJ.
    • Breast Cancer Res Treat. 2015 Jan;149(1):223-7. doi: 10.1007/s10549-014-3218-x. Epub 2014 Dec 6.
    • Molecular testing for the BRCA1 and BRCA2 Ashkenazi Jewish founder mutations: a report on the College of American Pathologists proficiency testing surveys.
    • Tafe LJ, Datto MB, Palomaki GE, Lacbawan FL.
    • Genet Med. 2015 Jan;17(1):58-62. doi: 10.1038/gim.2014.77. Epub 2014 Jun 19.
    • Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial.
    • Manchanda R, Loggenberg K, Sanderson S, Burnell M, Wardle J, Gessler S, Side L, Balogun N, Desai R, Kumar A, Dorkins H, Wallis Y, Chapman C, Taylor R, Jacobs C, Tomlinson I, McGuire A, Beller U, Menon U, Jacobs I.
    • J Natl Cancer Inst. 2014 Nov 30;107(1):379. doi: 10.1093/jnci/dju379. Print 2015 Jan.

    Press: Current way of detecting gene mutations misses people at high risk of cancer. (Medical Xpress)

    Press: 'Screen more' for cancer risk genes. (BBC Health)

    Press: Population Genetic Testing Favored for BRCA1/BRCA2 Mutations in Ashkenazi-Jewish Women. (Medscape / Reuters Health)

    • Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.
    • Manchanda R, Legood R, Burnell M, McGuire A, Raikou M, Loggenberg K, Wardle J, Sanderson S, Gessler S, Side L, Balogun N, Desai R, Kumar A, Dorkins H, Wallis Y, Chapman C, Taylor R, Jacobs C, Tomlinson I, Beller U, Menon U, Jacobs I.
    • J Natl Cancer Inst. 2014 Nov 30;107(1):380. doi: 10.1093/jnci/dju380. Print 2015 Jan.

    Press: Current way of detecting gene mutations misses people at high risk of cancer. (Medical Xpress)

    Press: Population Genetic Testing Favored for BRCA1/BRCA2 Mutations in Ashkenazi-Jewish Women. (Medscape / Reuters Health)

    • Unknown significance.
    • Couzin-Frankel J.
    • Science. 2014 Dec 5;346(6214):1167-70. doi: 10.1126/science.346.6214.1167.

    Press: Feature: Peering into my genome (Science)

    • FMR1 CGG allele length in Israeli BRCA1/BRCA2 mutation carriers and the general population display distinct distribution patterns.
    • Laitman Y, Ries-Levavi L, Berkensdadt M, Korach J, Perri T, Pras E, Friedman E.
    • Genet Res (Camb). 2014 Oct 8;96:e11. doi: 10.1017/S0016672314000147.
    • Breast cancer incidence rates among orthodox Jewish women.
    • Tkatch R, Schwartz K, Shore RD, Penner LA, Simon MS, Albrecht TL.
    • J Immigr Minor Health. 2014 Oct;16(5):1007-10. doi: 10.1007/s10903-013-9822-8.
    • Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.
    • Gabai-Kapara E, Lahad A, Kaufman B, Friedman E, Segev S, Renbaum P, Beeri R, Gal M, Grinshpun-Cohen J, Djemal K, Mandell JB, Lee MK, Beller U, Catane R, King MC, Levy-Lahad E.
    • Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):14205-10. doi: 10.1073/pnas.1415979111. Epub 2014 Sep 5.

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: Population screening for BRCA1/2

    • Genetic Testing For All: Is It Eugenics?
    • Ricki Lewis.
    • DNA Science Blog, 2014 Sep 18.
    • Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award.
    • King MC, Levy-Lahad E, Lahad A.
    • JAMA. 2014 Sep 17;312(11):1091-2. doi: 10.1001/jama.2014.12483.

    Comments on NSGC Discussion Forum

    Subject: NSGC Statement on BRCA Testing Over 30

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: Population screening for BRCA1/2

    Letter:

    Proposed Shift in Screening for Breast Cancer.

    Letter, Comment:

    Proposed Shift in Screening for Breast Cancer-Reply.

    • Beyond family history: Should all women be screened for BRCA breast cancer genes?
    • Meredith Knight.
    • Genetic Literacy Project, 2014 Sep 9.
    • The K898E germline variant in the PP1-binding motif of BRCA1 causes defects in DNA Repair.
    • Chen BY, Huang CH, Lin YH, Huang CC, Deng CX, Hsu LC.
    • Sci Rep. 2014 Jul 24;4:5812. doi: 10.1038/srep05812.
    • BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts.
    • Lucas AL, Frado LE, Hwang C, Kumar S, Khanna LG, Levinson EJ, Chabot JA, Chung WK, Frucht H.
    • Cancer. 2014 Jul 1;120(13):1960-7. doi: 10.1002/cncr.28662. Epub 2014 Apr 15.
    • Incorporating genetic testing ancestry results into medical decisions.
    • Farrell RM, Pederson H, Padia S.
    • Virtual Mentor. 2014 Jun 1;16(6):428-33. doi: 10.1001/virtualmentor.2014.16.06.ecas2-1406.
    • Cultural Aspects of Healthy BRCA Carriers From Two Ethnocultural Groups.
    • Navarro de Souza A, Groleau D, Loiselle CG, Foulkes WD, Wong N.
    • Qual Health Res. 2014 May;24(5):665-81. doi: 10.1177/1049732314528756. Epub 2014 Apr 1.
    • Surgically treated ovarian endometriosis association with BRCA1 and BRCA2 mutations.
    • Aviel-Ronen S, Soriano D, Shmuel E, Schonman R, Rosenblatt K, Zadok O, Vituri A, Seidman D, Barshack I, Cohen Y.
    • Pathol Res Pract. 2014 Apr;210(4):250-5. doi: 10.1016/j.prp.2013.12.011. Epub 2014 Jan 10.
    • BRCA1/2 mutations and FMR1 alleles are randomly distributed: a case control study.
    • Dagan E, Cohen Y, Mory A, Adir V, Borochowitz Z, Raanani H, Kurolap A, Melikhan-Revzin S, Meirow D, Gershoni-Baruch R.
    • Eur J Hum Genet. 2014 Feb;22(2):277-9. doi: 10.1038/ejhg.2013.281. Epub 2013 Nov 27.
    • Mapping Jewish Identities: Migratory Histories and the Transnational Re-Framing of ‘Ashkenazi BRCA Mutations’ in the UK and Brazil.
    • Mozersky J, Gibbon S.
    • In: Breast Cancer Gene Research and Medical Practices: Transnational Perspectives in the Time of BRCA. Oxon (UK): Routledge; 2014. Gibbon S, Joseph G, Mozersky J, zur Nieden A, Palfner S, editors. Wellcome Trust–Funded Monographs and Book Chapters.
    • Breast cancer risk prediction accuracy in Jewish Israeli high-risk women using the BOADICEA and IBIS risk models.
    • Laitman Y, Simeonov M, Keinan-Boker L, Liphshitz I, Friedman E.
    • Genet Res (Camb). 2013 Dec;95(6):174-7. doi: 10.1017/S0016672313000232. Epub 2014 Feb 10.
    • Ask Well: Genetic Testing for Breast Cancer.
    • Roni Caryn Rabin.
    • New York Times. Ask Well. 2013 Nov 27.
    • BRCA mutations and outcome in epithelial ovarian cancer (EOC): experience in ethnically diverse groups.
    • Safra T, Lai WC, Borgato L, Nicoletto MO, Berman T, Reich E, Alvear M, Haviv I, Muggia FM.
    • Ann Oncol. 2013 Nov;24 Suppl 8:viii63-viii68. doi: 10.1093/annonc/mdt315.
    • Experience of BRCA1/2 mutation-negative young women from families with hereditary breast and ovarian cancer: a qualitative study.
    • Macrae L, de Souza AN, Loiselle CG, Wong N.
    • Hered Cancer Clin Pract. 2013 Oct 16;11(1):14. doi: 10.1186/1897-4287-11-14.
    • Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort.
    • Greenup R, Buchanan A, Lorizio W, Rhoads K, Chan S, Leedom T, King R, McLennan J, Crawford B, Kelly Marcom P, Shelley Hwang E.
    • Ann Surg Oncol. 2013 Oct;20(10):3254-8. doi: 10.1245/s10434-013-3205-1. Epub 2013 Aug 22.
    • A Dispatch from the Genetic Frontier.
    • Theo Bloom.
    • PLOS Biologue. 2013 Sep 24.
    • A comparison of the detection of BRCA mutation carriers through the provision of Jewish population-based genetic testing compared with clinic-based genetic testing.
    • Metcalfe KA, Poll A, Royer R, Nanda S, Llacuachaqui M, Sun P, Narod SA.
    • Br J Cancer. 2013 Aug 6;109(3):777-9. doi: 10.1038/bjc.2013.309. Epub 2013 Jun 18.
    • Clinicians' Attitudes toward General Screening of the Ashkenazi-Jewish Population for Prevalent Founder BRCA1/2 and LRRK2 Mutations.
    • Shkedi-Rafid S, Ofer-Bialer G, Meiner V, Calderon-Margalit R.
    • Public Health Genomics. [2013 Aug;];16(4):174-83. doi: 10.1159/000351592. Epub 2013 Jun 28.
    • High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions.
    • Lucas AL, Shakya R, Lipsyc MD, Mitchel EB, Kumar S, Hwang C, Deng L, Devoe C, Chabot JA, Szabolcs M, Ludwig T, Chung WK, Frucht H.
    • Clin Cancer Res. 2013 Jul 1;19(13):3396-403. doi: 10.1158/1078-0432.CCR-12-3020. Epub 2013 May 8.

    Research news:

    Delineating the effects BRCA1 and BRCA2 loss of heterozygosity in pancreatic cancer progression.

    • High mammographic density in women of Ashkenazi Jewish descent.
    • Caswell JL, Kerlikowske K, Shepherd JA, Cummings SR, Hu D, Huntsman S, Ziv E.
    • Breast Cancer Res. 2013 May 13;15(3):R40. doi: 10.1186/bcr3424.
    • Genetic variants associated with breast cancer risk for Ashkenazi Jewish women with strong family histories but no identifiable BRCA1/2 mutation.
    • Rinella ES, Shao Y, Yackowski L, Pramanik S, Oratz R, Schnabel F, Guha S, Leduc C, Campbell CL, Klugman SD, Terry MB, Senie RT, Andrulis IL, Daly M, John EM, Roses D, Chung WK, Ostrer H.
    • Hum Genet. 2013 May;132(5):523-36. doi: 10.1007/s00439-013-1269-4. Epub 2013 Jan 25.
    • Involvement of IGF-1R regulation by miR-515-5p modifies breast cancer risk among BRCA1 carriers.
    • Gilam A, Edry L, Mamluk-Morag E, Bar-Ilan D, Avivi C, Golan D, Laitman Y, Barshack I, Friedman E, Shomron N.
    • Breast Cancer Res Treat. 2013 Apr;138(3):753-60. doi: 10.1007/s10549-013-2502-5. Epub 2013 Apr 3.
    • Dealing with the unexpected: consumer responses to direct-access BRCA mutation testing.
    • Francke U, Dijamco C, Kiefer AK, Eriksson N, Moiseff B, Tung JY, Mountain JL.
    • PeerJ. 2013 Feb 12;1:e8. doi: 10.7717/peerj.8. Print 2013.

    Comments on NSGC Discussion Forum

    Subject: Current thoughts on 23andme?

    Press: Consumers have few negative reactions to the results of genetic testing for cancer mutations. (EurekAlert!)

    Press: Get ready for the risks of genetic testing. (CNN)

    • Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations.
    • Laitman Y, Feng BJ, Zamir IM, Weitzel JN, Duncan P, Port D, Thirthagiri E, Teo SH, Evans G, Latif A, Newman WG, Gershoni-Baruch R, Zidan J, Shimon-Paluch S, Goldgar D, Friedman E.
    • Eur J Hum Genet. 2013 Feb;21(2):212-6. doi: 10.1038/ejhg.2012.124. Epub 2012 Jul 4.
    • Frequency of Triple-Negative Breast Cancer in BRCA1 Mutation Carriers: Comparison Between Common Ashkenazi Jewish and Other Mutations.
    • Tung N, Garber JE, Lincoln A, Domchek SM.
    • J Clin Oncol. 2012 Dec 10;30(35):4447-8. doi: 10.1200/JCO.2012.44.5635. Epub 2012 Oct 22.

    Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women.

    • Germline mutations in RAD51C in Jewish high cancer risk families.
    • Kushnir A, Laitman Y, Shimon SP, Berger R, Friedman E.
    • Breast Cancer Res Treat. 2012 Dec;136(3):869-74. doi: 10.1007/s10549-012-2317-9. Epub 2012 Nov 2.
    • Clinical significance of large rearrangements in BRCA1 and BRCA2.
    • Judkins T, Rosenthal E, Arnell C, Burbidge LA, Geary W, Barrus T, Schoenberger J, Trost J, Wenstrup RJ, Roa BB.
    • Cancer. 2012 Nov 1;118(21):5210-6. doi: 10.1002/cncr.27556. Epub 2012 Apr 27.
    • BRCA1 And BRCA2 analysis of Argentinean breast/ovarian cancer patients selected for age and family history highlights a role for novel mutations of putative south-American origin.
    • Solano AR, Aceto GM, Delettieres D, Veschi S, Neuman MI, Alonso E, Chialina S, Chacón RD, Renato MC, Podestá EJ.
    • Springerplus. 2012 Sep 25;1:20. doi: 10.1186/2193-1801-1-20. eCollection 2012.
    • Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families.
    • Catucci I, Milgrom R, Kushnir A, Laitman Y, Paluch-Shimon S, Volorio S, Ficarazzi F, Bernard L, Radice P, Friedman E, Peterlongo P.
    • Fam Cancer. 2012 Sep;11(3):483-91. doi: 10.1007/s10689-012-9540-8.
    • Association of a HOXB13 variant with breast cancer.
    • Alanee S, Couch F, Offit K.
    • N Engl J Med. 2012 Aug 2;367(5):480-1. doi: 10.1056/NEJMc1205138.
    • Grace Rock's consent.
    • Ross TS.
    • Endocr Relat Cancer. 2012 Jul 22;19(4):C29-31. doi: 10.1530/ERC-12-0186. Print 2012 Aug.
    • Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes.
    • Johnston JJ, Rubinstein WS, Facio FM, Ng D, Singh LN, Teer JK, Mullikin JC, Biesecker LG.
    • Am J Hum Genet. 2012 Jul 13;91(1):97-108. doi: 10.1016/j.ajhg.2012.05.021. Epub 2012 Jun 14.

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: articles needed

    • BRCA genetic testing of individuals from families with low prevalence of cancer: experiences of carriers and implications for population screening.
    • Shkedi-Rafid S, Gabai-Kapara E, Grinshpun-Cohen J, Levy-Lahad E.
    • Genet Med. 2012 Jul;14(7):688-94.
    • Prevalence of 185delAG and 5382insC mutations in BRCA1, and 6174delT in BRCA2 in women of Ashkenazi Jewish origin in southern Brazil.
    • Dillenburg CV, Bandeira IC, Tubino TV, Rossato LG, Dias ES, Bittelbrunn AC, Leistner-Segal S.
    • Genet Mol Biol. 2012 Jul;35(3):599-602. doi: 10.1590/S1415-47572012000400009. Epub 2012 Aug 17.
    • Recurrent germline mutations in BRCA1 and BRCA2 genes in high risk families in Israel.
    • Laitman Y, Simeonov M, Herskovitz L, Kushnir A, Shimon-Paluch S, Kaufman B, Zidan J, Friedman E.
    • Breast Cancer Res Treat. 2012 Jun;133(3):1153-7. doi: 10.1007/s10549-012-2006-8. Epub 2012 Mar 8.

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: AJ Founder Mutations

    • Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening.
    • Metcalfe KA, Mian N, Enmore M, Poll A, Llacuachaqui M, Nanda S, Sun P, Hughes KS, Narod SA.
    • Breast Cancer Res Treat. 2012 Jun;133(2):735-40. doi: 10.1007/s10549-011-1941-0. Epub 2012 Jan 13.
    • Who's to blame? Accounts of genetic responsibility and blame among Ashkenazi Jewish women at risk of BRCA breast cancer.
    • Mozersky J.
    • Sociol Health Illn. 2012 Jun;34(5):776-90. doi: 10.1111/j.1467-9566.2011.01427.x. Epub 2012 Jan 18.
    • Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers.
    • Finkelman BS, Rubinstein WS, Friedman S, Friebel TM, Dubitsky S, Schonberger NS, Shoretz R, Singer CF, Blum JL, Tung N, Olopade OI, Weitzel JN, Lynch HT, Snyder C, Garber JE, Schildkraut J, Daly MB, Isaacs C, Pichert G, Neuhausen SL, Couch FJ, van't Veer L, Eeles R, Bancroft E, Evans DG, Ganz PA, Tomlinson GE, Narod SA, Matloff E, Domchek S, Rebbeck TR.
    • J Clin Oncol. 2012 Apr 20;30(12):1321-8. doi: 10.1200/JCO.2011.37.8133. Epub 2012 Mar 19.
    • The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers.
    • Laitman Y, Kuchenbaecker KB, Rantala J, Hogervorst F, Peock S, Godwin AK, Arason A, Kirchhoff T, Offit K, Isaacs C, Schmutzler RK, Wappenschmidt B, Nevanlinna H, Chen X, Chenevix-Trench G, Healey S, Couch F, Peterlongo P, Radice P, Nathanson KL, Caligo MA, Neuhausen SL, Ganz P, Sinilnikova OM, McGuffog L, Easton DF, Antoniou AC, Wolf I, Friedman E.
    • Breast Cancer Res Treat. 2012 Apr;132(3):1119-26. doi: 10.1007/s10549-011-1938-8. Epub 2012 Jan 3.
    • Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?
    • Bernholtz S, Laitman Y, Kaufman B, Shimon-Paluch S, Friedman E.
    • Breast Cancer Res Treat. 2012 Apr;132(2):669-73. doi: 10.1007/s10549-011-1886-3. Epub 2011 Nov 24.
    • Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer.
    • Gallagher DJ, Cronin AM, Milowsky MI, Morris MJ, Bhatia J, Scardino PT, Eastham JA, Offit K, Robson ME.
    • BJU Int. 2012 Mar;109(5):713-9. doi: 10.1111/j.1464-410X.2011.10292.x. Epub 2011 Jul 14.
    • Implications for cancer genetics practice of pro-actively assessing family history in a General Practice cohort in North West London.
    • Kohut K, D'Mello L, Bancroft EK, Thomas S, Young MA, Myhill K, Shanley S, Briggs BH, Newman M, Saraf IM, Cox P, Scambler S, Wagman L, Wyndham MT, Eeles RA, Ferris M.
    • Fam Cancer. 2012 Mar;11(1):107-13. doi: 10.1007/s10689-011-9482-6.
    • Appendectomy and cancer risk in Jewish BRCA1 and BRCA2 mutation carriers.
    • Bernholtz S, Jakobson-Setton A, Korach J, Ben Baruch G, Laitman Y, Friedman E.
    • Breast Cancer Res Treat. 2012 Feb;131(3):981-5. doi: 10.1007/s10549-011-1807-5. Epub 2011 Oct 9.
    • Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer.
    • Stadler ZK, Salo-Mullen E, Patil SM, Pietanza MC, Vijai J, Saloustros E, Hansen NA, Kauff ND, Kurtz RC, Kelsen DP, Offit K, Robson ME.
    • Cancer. 2012 Jan 15;118(2):493-9. doi: 10.1002/cncr.26191. Epub 2011 May 19.